

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
-  BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/53, 33/567, 33/542, C07K 2/00, 4/00, 16/00		A1	(11) International Publication Number: WO 99/50664
			(43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/US99/07168		(74) Agent: STEVENS, Lauren, L.; Affymax Research Institute, 4001 Miranda Avenue, Palo Alto, CA 94304 (US).	
(22) International Filing Date: 1 April 1999 (01.04.99)			
(30) Priority Data: 09/053,611 1 April 1998 (01.04.98)		US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/053,611 (CON) Filed on 1 April 1998 (01.04.98)			
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): NORTHROP, Jeffrey, Paul [US/US]; 643 Vista Drive, Redwood City, CA 94062 (US). HART, Charles, Praray [US/US]; 725 Leona Lane, Mountain View, CA 94040 (US). SCHATZ, Peter, Joseph [US/US]; 2080 Marich Way #15, Mountain View, CA 94040 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD; SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
(54) Title: COMPOSITIONS AND METHODS FOR DETECTING LIGAND-DEPENDENT NUCLEAR RECEPTOR AND COACTIVATOR INTERACTIONS			
(57) Abstract <p>The invention provides a method based upon the two hybrid system for examining the interactions of nuclear receptors. The invention is additionally directed to compositions for use in the assay and a method of identifying ligands of nuclear receptors and their coactivator or corepressor proteins.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMPOSITIONS AND METHODS FOR DETECTING LIGAND-DEPENDENT
NUCLEAR RECEPTOR AND COACTIVATOR INTERACTIONS

5 TECHNICAL FIELD

The invention relates to the fields of molecular genetics and pharmacology. The invention provides methods and compositions for determining the capability of a compound, a macromolecular species, or of a stimulatory effector to produce a conformational change in a predetermined nuclear receptor and/or its accessory protein(s), typically to agonize or antagonize a 10 ligand-induced activation of the nuclear receptor. An aspect of the invention can provide a means for identifying agents which are pharmacological agonists or antagonists for one or more predetermined nuclear receptor species. An aspect of the invention relates to a method of rank-ordering a set of compounds with respect to each compound's ability to affect an interaction between one or more nuclear receptor species and a plurality of coactivator and/or corepressor species or similar interfaces; 15 the rank-ordering provides a dataset for identifying pharmacologically active agonists, antagonists, partial agonists, potentiators, and the like.

BACKGROUND OF THE INVENTION

20 A variety of nuclear receptors exist in animal cells and generally function to effectuate transcriptional regulation on one or more subsets of regulable genes. Most often, the nuclear receptor exhibits a high-affinity binding interaction with one or more species of hydrophobic ligand. These ligand binding interactions can produce a conformational change in the nuclear receptor. The conformational change induced by ligand binding modifies the ability of the nuclear receptor to interact 25 with certain specific receptor-binding DNA sequences and/or to interact with other nuclear proteins (e.g., transcription factors, coactivators, corepressors), so as to modulate the transcription of genes having the specific receptor-binding DNA sequence(s) located so as to influence the transcription of the gene. In one model of steroid receptor action, a ligand-induced conformational change in a ligand-binding domain unmasks a DNA-binding activity in another structural domain of the steroid receptor 30 protein. In the absence of this ligand-induced conformational change, the ligand-binding domain represses the DNA binding activity of the linked structural domain. It has been recently shown that one or more superfamily of proteins, termed "coactivators" and "corepressors", respectively interact with nuclear receptors in a ligand-dependent fashion so as to effect transcriptional activation (coactivators) or so as to inhibit or silence transcription (corepressors) of genes which are 35 transcriptionally modulated by nuclear receptors.

Nuclear hormone receptors comprise a superfamily of over 40 transcription factors. About half of them are classical receptors for lipophilic ligands such as steroids and vitamins. The

nuclear hormone receptor gene superfamily encodes structurally related proteins that regulate transcription of target genes. These macromolecules include receptors for steroid and thyroid hormones, vitamins, retinoids, fatty acids, and other nuclear receptor proteins for which no ligands have been found, so-called "orphan receptors". These receptors have modular domains with readily identifiable structural features and sequence motifs. The DNA-binding domain ("DBD") directs the receptors to bind specific DNA sequences as monomers, homodimers, or heterodimers. The ligand-binding domain ("LBD") responds to binding of the cognate hormone; this domain and the amino terminal domain interact with other transcription factors, and with the coactivators and/or corepressors. Nuclear receptor-specific actions are derived from a combination of diverse elements, including availability of ligand, receptors, and nonreceptor factors; target-site structure; interactions with other proteins, such as the general transcription factors and very importantly with the coactivator and/or corepressor proteins.

The steroid/thyroid hormone receptor superfamily of ligand-activated transcription factors encompasses not only the receptors for steroids, thyroid hormone, retinoids and vitamin D, but also a large number of proteins whose functions and/or ligands are unknown and which are thus termed orphan receptors. This family of transcription factors integrates signals from ligands as well as from signal transduction pathways, resulting in alterations in mRNA and protein expression that are unique to the complex signals received. These nuclear receptors are implicated in the control of a wide range of physiological responses and homeostatic conditions, including cell differentiation, neoplasia, control of cellular metabolism, and neurological function. For a review of the steroid hormone receptor superfamily, see Ribiero RC (1995) Annu. Rev. Med. 46: 443-453.

There has been substantial interest in identifying ligands which interact with nuclear receptors and modulate the biological effects mediated by these nuclear receptors. Such ligands, whether agonistic or antagonistic to natural physiological ligands of the receptors, would serve as candidate pharmaceuticals for controlling the biological effects of nuclear receptor-mediated transcriptional control and the attendant physiological effects produced thereby. Unfortunately, most conventional assays for identifying potential ligands rely upon the use of libraries of radiolabeled compounds which are tested for their binding coefficient (e.g., via Scatchard analysis) to a purified nuclear receptor species. It is difficult and labor-intensive to obtain such libraries of radiolabeled compounds and then screen the library using binding assays. Furthermore, it has been found that a compound's binding constant is not necessarily predictive of its biological activity as a ligand. As a better proxy for ligand function, transcriptional assays have been developed to assay for ligand-induced transcriptional activation of a nuclear receptor as detected by transcription of a reporter sequence operably linked to a nuclear receptor response element and promoter.

Unfortunately, many of the transcriptional responses generated by ligand-activated nuclear receptors can be subtle and are frequently difficult to detect and/or quantify by conventional transcriptional assay procedures, which are relatively insensitive for monitoring expression of genes which are not abundantly transcribed. Furthermore, many of the conventional transcription assay 5 procedures are difficult to perform and entail problematic steps, such as requiring lysis of the cells being assayed. It is desirable to have a method for detecting ligands of predetermined nuclear receptors with high specificity, sensitivity, and selectivity. In particular, methods to reduce readout background noise that can obscure legitimate signals would find great use in the art for identifying novel pharmaceutical agents that are nuclear receptor ligands, as well as providing sensitive assays 10 for detection and quantitation of ligands which are environmental pollutants that activate nuclear receptors (e.g., TCDD).

Moreover, many nuclear receptor ligands, particularly steroids and steroid-like compounds, often exhibit pleiotropic biological effects through nuclear receptors. For example, both 15 estradiol and tamoxiphen bind to the estrogen receptor, but each compound can produce different biological effects and transcriptional profiles (i.e., the set of genes which are transcriptionally modulated by ligand presence) depending upon the tissue and cell-type involved.

Thus, there exists a need in the art for methods to efficiently identify agents which 20 modulate nuclear receptor function. It is important that such methods have the necessary levels of sensitivity and specificity for identifying bona fide nuclear receptor agonists and/or antagonists. The present invention fulfills these and other needs in the art.

The references discussed herein are provided solely for their disclosure prior to the 25 filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

SUMMARY OF THE INVENTION

In accordance with the foregoing, in one aspect of the invention are provided methods 30 for identifying agents which are agonists or antagonists for ligand-induced activation of a predetermined nuclear receptor. There are a variety of formats of the invention, and a plurality of formats may be multiplexed sequentially or in parallel to produce a discrimination profile of a test agent in order to categorize the pharmacological nature of the test agent (e.g., agonist, antagonist, 35 partial agonist, mixed agonist/antagonist, etc.), so as to enable dissecting the pleiotropic biological effects of nuclear receptor ligands and correlating the individual effects with chemical structure.

Positive Hybrid System: Coactivators

The methods of the invention typically employ a positive hybrid nuclear receptor signal transduction system, which typically comprises an intact eukaryotic host cell, comprising: (1) a LBD-TRX polynucleotide sequence encoding and expressing a ligand-activatable fusion protein (referred to herein as "LBD-TRX") which comprises a ligand binding domain ("LBD") of a predetermined nuclear receptor covalently linked, typically in polypeptide linkage, to a transcriptional activator domain ("AD") or alternatively to a DNA-binding domain ("DBD") of a predetermined transcription factor (generically, AD and DBD are referred to as "TRX" for convenience), (2) a CA-TRX polynucleotide sequence encoding and expressing a coactivator fusion protein (referred to herein as "CA-TRX") which comprises a domain of a nuclear receptor coactivator protein ("CA") capable of binding to said LBD of said predetermined nuclear receptor linked, typically in polypeptide linkage, to a transcriptional activator domain or alternatively to a DNA-binding domain of a predetermined transcription factor (collectively "TRX"), and (3) a reporter polynucleotide sequence comprising, in linear order, a transcriptional regulatory sequence which is responsive to said predetermined transcription factor and a reporter cassette encoding a sequence that confers a signal or detectable phenotype. The TRX components of the LBD-TRX protein and the CA-TRX protein should be functionally complementary; i.e., if the TRX of one fusion is a DBD, the TRX of the other fusion is an AD, and vice versa. Prior to contacting of the system with an agent which is an agonist ligand of the LBD, the transcriptional activity of the LBD-TRX and CA-TRX with respect to the reporter polynucleotide is substantially absent and the system substantially lacks functional expression of an encoded sequence of the reporter polynucleotide. Subsequent to contacting of the system with an agonist agent which produces an activated conformation of the LBD in the LBD-TRX fusion protein, the CA-TRX fusion protein functionally associates forming a LBD-TRX/CA-TRX complex that is transcriptionally active with respect to the reporter polynucleotide, whereupon the reporter cassette can be transcribed and functionally expressed under the control of the transcriptional regulatory sequence. Thus, functional expression of the reporter cassette serves to report whether the system has been contacted with an agent which induced an activated conformation of the LBD. Advantageously, in one variation, the reporter cassette encodes a cell surface reporter protein which can be detected and/or selected for on the basis of its presence on the surface of a cell membrane. In embodiments where the nuclear receptor signal transduction system consists of metabolically active cells having a polynucleotide sequence encoding the LBD-TRX fusion, the CA-TRX fusion, and a reporter polynucleotide sequence, the system is referred to as a CA-TRX reporter cell.

A nuclear receptor signal transduction system of the present invention can be used to evaluate one or more test agents for their ability to activate the LBD of a predetermined nuclear receptor. Typically, the ability to activate the LBD indicates an agonistic activity as referenced to the physiological ligand of the nuclear receptor. In this aspect of the invention, a test agent is applied to a

nuclear receptor signal transduction system and incubated for a suitable incubation period anticipated to be substantially sufficient for the agent to transduce a signal to the LBD. After the incubation period, the expression of the reporter cassette is determined by detecting the presence of the reporter. Test agents which produce a statistically significant increase in reporter as compared to background (e.g., placebo) are scored as receptor agonists. In embodiments where the nuclear receptor signal transduction system comprises a metabolically active intact reporter cell, typically a population of reporter cells is contacted with a test agent, and the ability of the test agent to function as a receptor agonist is determined by either the relative expression of detectable reporter above background as compared to a reference population of reporter cells under substantially equivalent conditions in the absence of said test agent. Dose-response data can be generated in this manner using a variety of different concentrations of the test agent.

In a variation, the method may be used to identify antagonists of a predetermined nuclear receptor LBD by determining the ability of a test agent to produce a statistically significant reduction in the expression the reporter by inhibiting the capacity of a unit dose of a predetermined activating ligand of the LBD from producing the amount of expression of the reporter as occurs in the absence of the test agent.

Positive Hybrid System: Corepressors

The invention can also employ a composition and method for identifying ligands which induce binding of a corepressor to the LBD. These systems typically employ a positive hybrid nuclear receptor signal transduction system (a "CR-TRX" system), which typically comprises an intact eukaryotic host cell, comprising: (1) a LBD-TRX polynucleotide sequence encoding and expressing a ligand-activatable fusion protein (referred to herein as "LBD-TRX") which comprises a ligand binding domain ("LBD") of a predetermined nuclear receptor covalently linked, typically in polypeptide linkage, to a transcriptional activator domain ("AD") or alternatively to a DNA-binding domain ("DBD") of a predetermined transcription factor (generically, AD and DBD are referred to as "TRX" for convenience), (2) a CR-TRX polynucleotide sequence encoding and expressing a corepressor fusion protein (referred to herein as "CR-TRX") which comprises a domain of a nuclear receptor corepressor protein ("CR") capable of binding to said LBD of said predetermined nuclear receptor linked, typically in polypeptide linkage, to a transcriptional activator domain or alternatively to a DNA-binding domain of a predetermined transcription factor (collectively "TRX"), and (3) a reporter polynucleotide sequence comprising, in linear order, a transcriptional regulatory sequence which is responsive to said predetermined transcription factor and a reporter cassette encoding a sequence that confers a signal or detectable phenotype. The TRX components of the LBD-TRX protein and the CR-TRX protein should be functionally complementary; i.e., if the TRX of one fusion is a DBD, the TRX of the other fusion is an AD, and vice versa. Prior to contacting of the system with an agent which is an agonist

ligand of the LBD, the transcriptional activity of the LBD-TRX and CR-TRX with respect to the reporter polynucleotide is substantially absent and the system substantially lacks functional expression of an encoded sequence of the reporter polynucleotide. Subsequent to contacting of the system with an agonist agent which produces an activated conformation of the LBD in the LBD-TRX fusion protein, 5 the CR-TRX fusion protein functionally associates forming a LBD-TRX/CR-TRX complex that is transcriptionally active with respect to the reporter polynucleotide, whereupon the reporter cassette can be transcribed and functionally expressed under the control of the transcriptional regulatory sequence. Thus, functional expression of the reporter cassette serves to report whether the system has been contacted with an agent which induced an activated conformation of the LBD.

10 Advantageously, in one variation, the reporter cassette encodes a cell surface reporter protein which can be detected and/or selected for on the basis of its presence on the surface of a cell membrane. In embodiments where the nuclear receptor signal transduction system consists of metabolically active cells having a polynucleotide sequence encoding the LBD-TRX fusion, the CR-TRX fusion, and a reporter polynucleotide sequence, the system is referred to as a CR-TRX reporter cell.

15

A nuclear receptor signal transduction system of the present invention can be used to evaluate one or more test agents for their ability to activate the LBD of a predetermined nuclear receptor and induce corepressor binding. Typically, the ability to activate the LBD in this manner indicates an antagonistic or partial (mixed) antagonistic activity as referenced to a physiological ligand 20 of the nuclear receptor. In this aspect of the invention, a test agent is applied to a CR-TRX system and incubated for a suitable incubation period anticipated to be substantially sufficient for the agent to transduce a signal to the LBD. After the incubation period, the expression of the reporter cassette is determined by detecting the presence of the reporter. Test agents which produce a statistically significant increase in reporter as compared to background (e.g., placebo) are scored as receptor 25 antagonists or partial (mixed) antagonists. In embodiments where the nuclear receptor signal transduction system comprises a metabolically active intact reporter cell, typically a population of reporter cells is contacted with a test agent, and the ability of the test agent to function as a receptor agonist is determined by either the relative expression of detectable reporter above background as compared to a reference population of reporter cells under substantially equivalent conditions in the 30 absence of said test agent. Dose-response data can be generated in this manner using a variety of different concentrations of the test agent.

In a variation, the method may be used to identify agonists or partial (mixed) agonists of a predetermined nuclear receptor LBD by determining the ability of a test agent to produce a 35 statistically significant reduction in the expression of the reporter by inhibiting the capacity of a unit dose of a predetermined antagonist ligand of the LBD from producing the amount of expression of the reporter as occurs in the absence of the test agent.

Reverse Hybrid System:Corepressor

In a variation, the invention provides a nuclear receptor signal transduction system, comprising a "reverse hybrid" reporter host cell containing: (1) an LBD-TRX polynucleotide sequence encoding a fusion protein comprising a ligand-binding domain of a nuclear receptor in polypeptide linkage a DBD or AD of a transcription factor; (2) a CR-TRX polynucleotide sequence encoding and expressing a corepressor fusion protein (referred to herein as "CR-TRX") which comprises a domain of a nuclear receptor corepressor protein ("CR") capable of binding to said LBD of said predetermined nuclear receptor linked, typically in polypeptide linkage, to a transcriptional activator domain or alternatively to a DNA-binding domain of a predetermined transcription factor (TRX), and (3) a relay (or signal inverter) gene encoding a protein which is efficiently expressed as a consequence of the LDB-TRX binding to the CR-TRX as a transcriptionally active complex, and (4) reporter gene comprising, in linear order, a transcriptional regulatory sequence responsive to said transcriptionally active complex, and a reporter cassette encoding a reporter, wherein the reporter gene is efficiently expressed then the product of the relay (or signal inverter) gene is substantially absent and is either poorly expressed or not expressed when the relay (or signal inverter) gene is efficiently expressed. In an aspect, the LBD is a functional portion of a steroid hormone superfamily receptor capable of binding a corepressor protein in the absence of activating ligand and capable of undergoing a stimulus-induced conformational change, such as by binding a known agonistic ligand, so as to reduce or abrogate binding to the corepressor. The reverse hybrid system facilitates identification of test agents that relieve corepressor binding to the LBD.

A reverse hybrid nuclear receptor signal transduction system of the present invention can be used to evaluate one or more test agents for their ability to activate the LBD of a predetermined nuclear receptor by relieving corepressor binding. Typically, the ability to activate the LBD indicates an agonistic activity as referenced to the physiological ligand of the nuclear receptor, however given the pleotropic nature of many nuclear receptor ligands, it is possible that some such agents will be agonistic with respect to certain effects and antagonistic with respect to others. In this aspect of the invention, a test agent is applied to a reverse hybrid nuclear receptor signal transduction system and incubated for a suitable incubation period anticipated to be substantially sufficient for the agent to transduce a signal to the LBD. After the incubation period, the expression of the reporter cassette is determined by detecting the presence of the reporter. Test agents which produce a statistically significant increase in reporter as compared to background (e.g., placebo) are scored as receptor agonists. In embodiments where the reverse hybrid nuclear receptor signal transduction system comprises a metabolically active intact reporter cell, typically a population of reporter cells is contacted with a test agent, and the ability of the test agent to function as a receptor agonist is determined by either the relative expression of detectable reporter above background as compared to a reference population of reporter cells under substantially equivalent conditions in the absence of

said test agent. Dose-response data can be generated in this manner using a variety of different concentrations of the test agent.

In a variation, the method may be used to identify antagonists of a predetermined nuclear receptor LBD by determining the ability of a test agent to produce a statistically significant reduction in the expression the reporter by inhibiting the capacity of a unit dose of a predetermined activating ligand of the LBD from producing the amount of expression of the reporter as occurs in the absence of the test agent.

10

Reverse Hybrid System:Coactivators

In a variation of the reverse hybrid system, a coactivator (CA) domain may be used instead of a corepressor (CR) domain, and the system can be used, for example, to identify agents that inhibit, abrogate, disrupt, diminish, interfere with, or otherwise antagonize the functional interaction of the LBD and the coactivator domain. Such agents need not necessarily interact with the ligand-binding pocket of the LBD, and, for example, may interact with a binding interface between the coactivator and the LBD, or at other sites. The method may be used to identify functional antagonists of a predetermined nuclear receptor LBD by determining the ability of a test agent to produce a statistically significant reduction or relative inhibition in the expression the reporter by inhibiting the capacity of a unit dose of a predetermined activating ligand of the LBD from producing the amount of expression of the reporter as occurs in the absence of the test agent.

The invention can also be modified to identify agents that modulate, either positively or negatively, binding interactions between an LBD and a coactivator or corepressor without said agents necessarily interacting with a bona fide ligand-binding domain of the LBD. Generally, these formats employ an LBD, or binding portion thereof, which is functionally constitutive (i.e., not ligand-dependent) for binding to a coactivator or corepressor, or a binding fragment thereof. Such constitutive LBD species can be found as natural variants, can be generated by mutagenesis and selection for constitutive function, or can be generated by employing a high-affinity bona fide ligand at high concentration or covalently attached to the ligand binding pocket (e.g., via photoaffinity labelling), or other means known to those skilled in the art. In such systems, the constitutive LBD and coactivator (or corepressor) are used in LBD-TRX and CA-TRX (or CR-TRX) fusions in a reverse hybrid system and agents are screened for their ability to inhibit the constitutive LBD:CA (or LBD:CR) interaction as measured by a positive readout of the reporter gene.

35.

Direct Interaction Methods

In a variation of the invention, direct physical interaction, measured as binding, between a LBD domain and a CA domain (or CR domain) as a consequence of ligand presence can

be determined. In an aspect, an LBD domain is immobilized on a capture surface and a soluble, labelled or epitope-tagged CA or CR domain is introduced under aqueous physiological conditions, either in the absence or presence of a known ligand or a test agent. A typical format of the direct method can be an ELISA, for illustration. Agents which produce a ligand-induced binding between the 5 immobilized LBD and the soluble, labelled or epitope-tagged CA (or CR), thereby resulting in the CA (or CR) becoming immobilized on the capture surface and retained following washing of the surface with a rinse solution substantially lacking soluble, labelled or epitope-tagged CA (or CR), and thus retained on the capture surface and detected by suitable means, can be identified as candidate ligands.

10

In a variation, the CA (or CR) can be immobilized on the capture surface and the LBD can be labelled or epitope-tagged. Epitope-tagged proteins can generally be detected by immunochemical methods using at least one antibody species that is specifically reactive with the epitope.

15

In a variation, the LBD species (or a multiplicity thereof) is immobilized on the capture surface and the soluble, labelled CA and/or CR species (or a multiplicity of species thereof) can be used to identify ligand-induced binding interactions or ligand-dependent relief of binding interactions between an LBD and a CA or CR (or multiple combinations thereof). In such variations, it is usually 20 preferable to employ distinctive labels or epitope-tags for each species of CA and/or CR, which can provide a basis for discrimination of which specie(s) of CA or CR bind to an LBD species (or a collection of LBD species) based upon unique detection of each label or tag on the capture surface. Vice versa, a CA or CR (or multiple species thereof) can be immobilized on the capture surface and multiple species of uniquely labeled or tagged LBDs may be used. In each case, a test agent can be 25 evaluated for its ability to produce a concentration-dependent binding between LBD and CA or CR species and compared to a parallel reaction lacking agent and/or to a parallel reaction lacking agent and containing a known ligand, either agonist or antagonist. Variations which employ multiple species of LBD are termed "LBD multiplexed" and variations which employ multiple species of CA or CR are termed "CA multiplexed" or "CR multiplexed", respectively. Test agents are categorized based on 30 their effect as an agonist, antagonist, or lack of such effect with respect to each combination of LBD and CA or CR. Concentration dependence and EC_{50} or IC_{50} values can be additional parameters for categorization of a test agent as an agonist or antagonist with regard to a particular end point.

Multiplexing of Formats

35

The invention employs several formats, such as those just described. These formats can be employed in parallel to provide a multiplexed format assay. A multiplexed format assay of the invention comprises at least two of the following: (1) positive hybrid system:coactivator, (2) positive

hybrid system:corepressor, (3) reverse hybrid system:coactivator, (4) reverse hybrid system:corepressor, (5) direct interaction assay, or (6) other art-know assay for identifying and/or quantifying ligand efficacy and/or potency as an antagonist or agonist of nuclear receptors. A preferred multiplex assay is a combination of (1) and (5). Additionally, an individual type of format 5 can be multiplexed with regard to LBD species employed and/or CA or CR species employed (e.g., a positive hybrid system with an estrogen receptor LBD and a second positive hybrid system with a thyroid hormone receptor LBD). Combinations of format-multiplexed and LBD-multiplexed, CA-multiplexed, and/or CR-multiplexed systems and methods can be used in an individual method embodiment to enhance sensitivity and/or selectivity of identification of agonists and antagonists of 10 nuclear receptors.

In embodiments where cell-based assays are multiplexed, it is often preferred to employ multiple distinct species of reporter cells in each assay chamber (e.g., well of a cell culture plate), with each species of reporter cell providing a distinguishable and detectable readout. In a 15 variation using cell-based assays, flow cytometry (which can include capillary cytometry) is used to detect readout signals, often with the use of diode lasers or tunable illumination sources in cases where the readout involves fluorescent signals.

Specificity of Bioeffect Fingerprinting

20 In an aspect, the invention provides a method for identifying a candidate pharmaceutical agent from a library of test agents, wherein the candidate pharmaceutical agent has a desired biological effect profile ("bioeffect fingerprint"). The method comprises: (1) performing n (where n is a number greater than 2, preferably greater than 3, and less than 10 billion) distinct assays of the invention individually using each discrete test agent (which may be a mixture) of the library so 25 as to obtain for each individual test agent measurements of at least n biological effects as detected as a ligand-induced conformational change or a binding interaction change in a discrete assay, (2) for each biological effect detected, assigning a score value (binary or quantitative) based upon the detection (or lack thereof) of a ligand-induced conformational change or binding interaction in each assay, separately, to generate a score matrix ("bioeffect fingerprint") for each agent, and (3) to 30 compare each agent's score matrix to an equivalent (i.e., representing the same assays under similar conditions) score matrix for one or more predetermined agonist(s) and/or antagonist(s), and thereby identify agents having score matrices substantially similar to the score matrix(es) of said predetermined agonist(s) or antagonist(s). The substantial identity determination may be made on the basis of the general knowledge and experience of a skilled practitioner in the art, and/or may be made on 35 the basis of a rank-ordering of matrix similarity (i.e., total number of matches), and/or may be made by electronic computation using a trained neural network implementation (e.g., BrainMaker running on a Windows platform trained with data from a plurality of predetermined agonists and/or antagonists in

similar assays), or by other means. This method provides identification of novel receptor ligands and their characterization based on bioeffect measurements made using in vitro assays and/or cell culture assays. In general, the predictive value of biological effects *in vivo* of such a multi-parameter method increase with score matrix size (i.e., score matrixes having at least 5 cells or elements, each 5 representing a distinct assay type, are preferred).

In an aspect, the invention also provides novel polypeptides comprising a binding amino acid sequence that is: (1) non-naturally occurring in a nuclear protein, and (2) predetermined to bind to a nuclear receptor, typically by interaction with a binding interface of a nuclear receptor at 10 which naturally-occurring coactivators and/or corepressors bind. These polypeptides and compositions thereof are candidate antagonists for coactivator or corepressor binding (e.g., competitive inhibitors), can be employed as a CA portion of a CA-TRX fusion or as a CR portion of a CR-TRX fusion for use in assays of the invention, such uses can include commercial sale as reagents, and for other uses apparent to those skilled in the art. Such binding amino acid sequences generally 15 comprise a LXXLL motif (wherein L is leucine and X is any of the conventional amino acids) and include, with regard to the LBD of the human estrogen receptor, the sequences shown in Fig. 16. The novel polypeptides are generally from 5 to 50,000 amino acids long, most usually from 10 to 500 amino acids long, and may comprise one or multiple species of such binding amino acid sequences, which may be repeated, and the remainder of the polypeptide may contain other naturally occurring 20 sequences (e.g., fusions to known proteins) and/or may contain random, pseudorandom, or defined sequence kernel amino acid sequence(s). Peptidomimetics having structural homology to the novel binding sequences are also provided according to methods known in the art; such peptidomimetics or constrained peptides can provide novel therapeutic drugs to provide agonism or antagonism of one or more nuclear receptor ligands.

25

In an aspect, the nuclear receptor signal transduction system may comprise a transgenic nonhuman animal having all or some somatic cells which are reporter cells. In this aspect, the transgenic nonhuman animal may be administered a test agent which may act indirectly (i.e, other than by binding to the LBD) or as an LBD ligand. Detection of reporter expression at a statistically- 30 significant level in said one or more somatic cell types indicates agonist activity of the test agent. In an embodiment, lymphocytes of said transgenic animal are reporter cells and are collected from said transgenic animal following administration of a test agent to the transgenic animal and a suitable incubation period; the relative abundance of lymphocytes expressing the reporter protein as referenced to lymphocytes from an untreated transgenic animal under similar conditions except 35 lacking administration of the test agent serves to identify the agonistic or antagonistic efficacy, if any, of the test compound for activation of the predetermined nuclear receptor *in vivo*.

In a variation, bioeffect fingerprinting allows profiling of a plurality of compounds (test agents), said profiling comprising contacting a compound (test agent) with a plurality of reporter cell species and/or non-cellular reporter assays in a plurality of individual discrete reaction vessels, with each discrete reaction vessel containing a unique test agent species, typically at a predetermined 5 concentration, and determining, by comparison to a parallel set of assays employing as test agents compounds having predetermined pharmaceutical activities, a bioeffect fingerprint for each test agent, comprising a tabulated data compilation, often in matrix format and stored electronically in an electronic computer, indicating the assay readouts for said test agent and the predetermined pharmaceutical activities most closely similar, based on statistical analysis, to a test agent, and 10 thereby categorizing test agents based upon similarities to known pharmaceutically active compounds.

Orphan Receptors

The methods and compositions of the present invention can be advantageously used to identify ligands to orphan receptors for which physiological ligands are unknown. Two-hybrid 15 systems can be employed to identify polypeptide sequences having binding activity with regard to the orphan receptor, and/or peptidomimetics can be employed to identify binding motifs which can mimic physiological coactivators and corepressors, even though such physiological coactivators and corepressors might remain unidentified.

20 Such compositions, reporter host cells, transgenic nonhuman animals, and kits find use as commercially marketable drug development reagents, sensitive diagnostic detection systems for environmental ligands (e.g., to assay polycyclic aromatic hydrocarbons in a sample by detecting their agonistic action on the Ah nuclear receptor and as reagents to titrate biopotency of a nuclear receptor ligand for preparation of pharmaceutical formulations.

25 Other features and advantages of the invention will be apparent from the following description of the drawings, preferred embodiments of the invention, the examples, and the claims.

BRIEF DESCRIPTION OF THE FIGURES

30 Fig. 1 is a schematic representation of an exemplary embodiment of a direct interaction assay format (ELISA) for measuring interaction of a nuclear receptor LBD with a binding fragment of steroid receptor coactivator-1 (SRC-1). The LBD of the nuclear receptor (ER = estrogen receptor, TR / = thyroid hormone receptor or form) fused in-frame to a glutathione S-transferase sequence (GST) to form the binding member for the nuclear receptor LBD which is immobilized on a 35 substrate indicated as a well surface, such as by electrostatic binding to a plastic 96-well plate. The coactivator member contains 3 leucine charged domains (LCDs) of SRC-1 fused in-frame to GST/MBP at the amino-terminus and fused in-frame to an antibody 179 epitope tag at the carboxy-terminus.

The LCD sequences are shown. The SRC-1 fusion member that is bound to the immobilized LBD is detected with a mouse antibody that specifically reacts with the 179 epitope and a second antibody (alkaline phosphatase conjugated antimouse Ab).

5 Fig. 2 shows the results of the direct interaction assay using ER LBD interacting with SRC-1. 0.5 μ g of purified GST-ER was used with varying amounts of crude bacterial lysate containing GST-SRC-1. The interaction is specific (GST control) and enhanced by estradiol.

10 Fig. 3 shows the results of the direct interaction assay using ER LBD interacting with SRC-1. 0.5 μ g of purified GST-ER was used with varying amounts of crude bacterial lysate containing GST-SRC-1. The interaction is specific (GST control) and enhanced by estradiol.

15 Fig. 4 shows results of a direct interaction assay of the TR and TR LBDs interacting with SRC-1. The indicated amounts of GST fusion proteins were used. The interaction is specific and dependent on T3.

20 Fig. 5 shows results of a direct interaction assay as a dose-response curve of T3 in promoting interaction between the TR and TR LBDs and SRC-1. T3 appears more potent on the receptor.

Fig. 6 shows a schematic portrayal of LRB-TRX, CA-TRX, and CR-TRX constructs used and the reporter polynucleotide of a two-hybrid system. "Receptor" indicates LBD-TRX, with the LBD exemplified by a generic nuclear receptor (NR) LBD with bound ligand (L); and the TRX domain represented by the VP16 acidic activation domain (VP16). "Coactivator" indicates a CA-TRX, with exemplary CA species being a portion of the SRC-1 protein, a portion of the CBP protein, or isolated LCD sequences from those proteins, the TRX domain is exemplified as the Gal4 DNA binding domain (DBD). "Corepressor" indicates a CR-TRX, with exemplary CR species being the interacting domains (ID1 or ID2) from SMRT or NcoR fused to the TRX domain as exemplified by Gal4 DNA binding domain (DBD). The reporter polynucleotide is exemplified as a UAS-TK-luciferase reporter containing binding sites for Gal4 DBD. CHO cells were triple transfected with these constructs and hormone added.

Fig. 7 shows data from a positive two-hybrid system as a dose-response curve showing that reporter (luciferase) is generated only when all three components (VP16ER, Gal4-SRC-1, and UAS-TK-luciferase) are transfected together, and that the response is dose-dependent with respect to estradiol concentration.

Fig. 8 shows data from a positive two-hybrid system as a dose-response curve showing that reporter (luciferase) is generated only when all three components (VP16TR, Gal4-SRC-1, and UAS-TK-luciferase) are transfected together, and that the response is dose-dependent with respect to T3 concentration.

5

Fig. 9 shows coactivator/corepressor interactions with TR LBD in the positive two-hybrid system. NcoR ID1, and to a lesser extent SMRT ID1 interact with TR LBD, but neither ID2 interacts strongly with the LBD. T3 induced dissociation of the corepressor fragments at significantly lower concentrations than is required to recruit a coactivator.

10

Fig. 10 shows coactivator/corepressor interactions with ER LBD in the positive two-hybrid system. NcoR ID1, and to a lesser extent SMRT ID1 interact with ER LBD, but neither ID2 interacts strongly with the LBD. None of the four IDs interact significantly with the ER LBD in the absence of ligand.

15

Fig. 11 shows a schematic portrayal of a method for identifying novel LCD sequences from libraries of displayed peptides. Peptide libraries were constructed by fusing sequences to the Lac repressor (LacI). The encoding plasmid contains operator sites so that a bacterial lysate contains the displayed peptides bound to the encoding plasmid. The library was screened with immobilized 20 GST-ER in the presence of estradiol in four rounds of enrichment.

Fig. 12 shows ELISA signals for LacI-fused peptides obtained from either a focused (-LXXLL-) or random (-XXXXX-) 15mer library in the presence of ER and estradiol.

25

Fig. 13 shows the sequences of LacI-fused peptides obtained by screening the library by ER panning. The top set of sequences was obtained from the focused (-LXXLL-) library and the bottom set was obtained from the random sequence (-XXXXX-) library. Notable amino acids are highlighted.

30

Fig. 14 shows ELISA data from the fourth round selectants of the LacI-fusions (tetravalent reagent) which were subcloned as a population into an MBP vector (monovalent reagent) and random clones tested without estradiol. Control is SRC-1 fragment (597-781) containing the 3 LCDs.

35

Fig. 15 shows ELISA data from the fourth round selectants of the LacI-fusions (tetravalent reagent) which were subcloned as a population into an MBP vector (monovalent reagent) and random clones tested with estradiol. Control is SRC-1 fragment (597-781) containing the 3 LCDs.

Note the estradiol dependence of many of the clones for interaction with ER (compare data in Fig. 14 with Fig. 15).

Fig. 16 shows the sequences of the selected clones. Notable amino acid residues are 5 highlighted.

Fig. 17 shows a schematic hypothetical example of bioeffect fingerprinting using a two dimensional score matrix.

10 DETAILED DESCRIPTION

All publications cited herein are incorporated herein in their entirety as if reproduced verbatim.

DEFINITIONS

15 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

20

As used herein, the term "coactivator" is any limiting factor that enhances the transcriptional activity of a nuclear receptor without substantially altering basal transcription with respect to at least one gene that can be transcriptionally regulated by the nuclear receptor in a ligand-dependent manner, and which binds to the nuclear receptor via direct protein-protein contact(s),

25 typically also in a ligand-dependent or AF-2 domain-dependent manner. Examples of some coactivators include, but are not limited to, SRC-1, ERAP140, RIP140, RIP160, Trip1, SWI1/SNF, ARA70, RAP46, TIF1, CBP, p300, TIF2, GRIP1, TRAP complex proteins, and other such proteins as are known in the art, including those described in Glass et al. (1997) *Curr. Opin. Cell Biol.* 9: 222 or Horwitz et al. (1996) *Mol. Endocrin.* 10: 1167. Coactivators typically contain at least one -LXXLL- motif (LCD), typically at least two or three such motifs. Coactivators typically bind to LBDs in an AF-2 dependent manner. Coactivators can include amino acid sequences which are not found in nature but which are identified by a peptide screening method as binding to a LBD of a nuclear receptor in a ligand-dependent manner.

30

35 As used herein the term "corepressor" is any limiting proteinaceous factor that inhibits transcription after being tethered to a promoter by DNA-bound receptors or which blocks binding of a coactivator; factors whose binding to receptors is ligand-regulated; and factors whose inhibitory effect

on transcription can be relieved in a ligand-dependent manner. Examples of some corepressors include, but are not limited to, N-Cor, SMRT, calcyclin, TRUP, and Tup1, and other such proteins as are known in the art, including those described in Glass et al. (1997) *Curr. Opin. Cell Biol.* 9: 222 or Horwitz et al. (1996) *Mol. Endocrin.* 10: 1167. Corepressors typically contain at least one or more 5 interaction domains (IDs), typically at least two or three such motifs.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage (*Immunology - A Synthesis*, 2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Massachusetts (1991), which is incorporated herein by reference).

- 10 Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as L,D-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, D-carboxyglutamate, D-N,N,N-trimethyllysine, N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, D-N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the righthand direction is the carboxy-terminal direction, in accordance with standard usage and convention. Similarly, unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide 15 sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".
- 20
- 25

As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity). 30 Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a 35 group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids

substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

The term "fragment" as used herein refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring (e.g., mature protein) sequence deduced, for example, from a full-length cDNA sequence of a coactivator, corepressor, or nuclear receptor. Fragments typically are at least 14 amino acids long, preferably at least 20 amino acids long, usually at least 50 amino acids long or longer and contain interaction interfaces such as LCDs, IDs, or AF-2.

10

The term "analog" as used herein refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an LBD, CA, or CR, and which has specific binding to a nuclear receptor, CA, or CR species. Typically, analog polypeptides comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, most usually being as long as full-length naturally-occurring polypeptide

15 The term "polypeptide" is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein, fragments, and analogs are species of the polypeptide genus.

20 The term "naturally-occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally-occurring. As used herein, laboratory strains of rodents which may have been selectively bred according to classical genetics are considered naturally-occurring animals.

25 As used herein, the term "LBD" or "ligand-binding domain" refers to the protein domain of a nuclear receptor, such as a steroid superfamily receptor or other suitable nuclear receptor as discussed herein, which binds a physiological ligand (e.g., a steroid hormone) and thereupon undergoes a conformational change and/or altered intermolecular interaction with an associated protein so as to confer a detectable activity upon a second, linked functional domain. When a suitable efficacious ligand interacts with the LBD and forms a liganded complex with an agonist, the LBD is activated and one or more coactivator species become bound. When a suitable efficacious ligand interacts with the LBD and forms a liganded complex with an antagonist, or in some cases in the absence of bound ligand, the LBD binds to one or more corepressor species.

An agonist ligand is defined herein as a ligand which, when bound by the LBD, induces a conformational change and/or alteration of an intermolecular or intermolecular interaction of the LBD so as to induce binding of coactivator and/or dissociation of corepressor. An antagonist ligand is defined herein as a ligand which opposes the effect of an agonist ligand, generally by dose-
5 dependent competitive binding, or by otherwise inducing or stabilizing binding of the LBD to a corepressor or inhibiting LBD binding to one or more coactivator species. Nuclear receptor LBDs are known to and/or can be identified by those skilled in the art and as described herein. Exemplary LBDs are obtained from steroid hormone receptors (e.g., ER, GR, PR, AR, ECR), retinoic acid receptors (e.g., RAR, RXR, RZR), peroxisome proliferator activator receptors (e.g., PPARs), thyroxine (T3)
10 receptor (TR), vitamin D receptor (e.g., VDR), and farnesoid receptor (e.g., FXR), aryl hydrocarbon receptor (Ah) orphan nuclear receptors, among others. The invention is not limited to known nuclear receptors, but can employ LBDs from any suitable nuclear receptor having an LBD which, in the absence of bound ligand, binds corepressor and/or fails to bind coactivator species.

15 As used herein, the term "LBD-TRX" and "LBD-TRX fusion protein" refer to a polypeptide comprising: (1) a portion of a nuclear receptor (e.g., a steroid receptor superfamily member) which is capable of binding a predetermined ligand species, typically a physiological ligand (e.g., a steroid hormone), with an affinity of at least about 1×10^{-8} M and which, in the absence of bound ligand, can bind corepressor and/or fails to bind one or more coactivator species which can
20 become bound in ligand-dependent manner; and (2) a catalytically active portion of a transcription factor DBD or AD. In some embodiments, a polypeptide spacer of about 1-25 amino acids may separate the LBD portion from the TRX portion. Spacers are preferably noninterfering sequences (i.e., which permit the desired functioning of the LBD-TRX in a cell nucleus), and can be readily determined and selected by the practitioner. In some embodiments, amino-terminal and/or carboxy-terminal
25 extensions of additional amino acids in noninterfering sequences can be present. For typical LBD-TRX species of the invention, the linear order of the LBD and TRX, from amino-terminus to carboxy-terminus, can be varied so long as the desired function, ligand-inducible activation of binding to coactivator and/or dissociation of corepressor with the LBD-TRX fusion protein, is retained.

30 As used herein, the term "cell surface reporter" refers to a protein which localizes to the plasma membrane of a host cell and a portion of the protein is exposed to the extracellular region (e.g., an integral membrane protein or a transmembrane glycoprotein, an engineered fusion between a detection protein and a membrane tether sequence), wherein said extracellular portion can be bound by a specific antibody or other ligand with an affinity of at least about 1×10^{-7} M and/or wherein
35 said extracellular portion can catalyze a detectable conversion of a substrate to a product. The term cell surface reporter also refers to a polynucleotide sequence encoding such a cell surface protein. Various cell surface proteins can be used as cell surface reporters, including fusion proteins

comprising at least one segment (e.g., an epitope of at least about 3 consecutive amino acids) that is not present in a naturally-occurring cell surface protein. For example but not limitation, the following may be used as cell surface reporters: a CD (cluster of differentiation) antigen present on cells of a hematopoietic lineage (e.g., CD2, CD4, CD8, CD21, etc.); β -glutamyltranspeptidase; an adhesion protein (e.g., ICAM-1, ICAM-2, ELAM-1, VCAM-1), spike glycoproteins of enveloped viruses (e.g., glycoprotein H of human cytomegalovirus (hCMV)), and the membrane-bound form of an immunoglobulin μ chain. Also for example but not limitation, a fusion protein between a transmembrane protein and a β -galactosidase protein may compose a cell surface reporter (i.e., a fusion protein having β -galactosidase sequences linked to a β -glutamyltranspeptidase heavy subunit); 5 cells bearing such fusion proteins can be affinity enriched using an immobilized anti- β -galactosidase antibody. A preferred cell surface reporter protein is a fusion of an enzyme, or a catalytically active portion thereof, to a membrane tether sequence, particularly where the enzyme produces a detectable conversion of substrate to product and wherein the host cell membrane is substantially impermeable to said substrate (e.g., luciferase). Preferably, a cell surface reporter protein is a protein which is not 10 normally expressed at significant levels on the host cells. Since luciferase is an invertebrate protein, fusion proteins comprising luciferase are preferred cell surface reporters for use with mammalian host cells. Numerous other specific examples of suitable cell surface reporters, such, for example, various cloned CD ("cluster of differentiation") antigens, are known to those of skill in the art (e.g., from the literature and GenBank™; such as CD2 GenBank sequence files: Humcd21, Humcd22, Humcd23, 15 Humcd24, and Humcd25, and Muscd21, Muscd22, Muscd23, Muscd24, and Muscd25) and may be 20 selected for use in the methods and polynucleotide constructs of the invention on the basis of the practitioner's desired application.

As used herein, the terms "expression cassette" refers to a polynucleotide comprising 25 a promoter sequence and, optionally, an enhancer and/or silencer element(s), operably linked to a structural sequence, such as a cDNA sequence or genomic DNA sequence. In some embodiments, an expression cassette may also include polyadenylation site sequences to ensure polyadenylation of transcripts. If the encoded protein is to be secreted or retained in the cell membrane, a signal sequence is generally encoded at the amino-terminal portion of the encoding sequence. When an 30 expression cassette is transferred into a suitable host cell, the structural sequence is transcribed from the expression cassette promoter, and a translatable message is generated, either directly or following appropriate RNA splicing. Typically, an expression cassette comprises: (1) a promoter, such as an SV40 early region promoter, HSV *tk* promoter or phosphoglycerate kinase (*pgk*) promoter, CMV promoter, Sr promoter or other suitable promoter known in the art, (2) a cloned polynucleotide 35 sequence, such as a cDNA or genomic fragment ligated to the promoter in sense orientation so that transcription from the promoter will produce a RNA that encodes a functional protein, and (3) a polyadenylation sequence. For example and not limitation, an expression cassette of the invention

may comprise the cDNA expression cloning vectors, pcD and NMT (Okayama H and Berg P (1983) Mol. Cell. Biol. 3: 280; Okayama H and Berg P (1985) Mol. Cell. Biol. 5: 1136, incorporated herein by reference) or other preferred expression vectors known and available in the art. The transcriptional regulatory sequences in an expression cassette is selected by the practitioner based on the intended 5. application; depending upon the specific use, transcription regulation can employ inducible, repressible, constitutive, cell-type specific, developmental stage-specific, sex-specific, or other desired type of transcriptional regulatory sequence.

As used herein, the term "reporter polynucleotide" refers to a polynucleotide 10 sequence comprising, in linear order, an operably linked transcriptional regulatory sequence and a reporter cassette. In a variation, the reporter polynucleotide encodes a selectable marker which can be selected for in order to ensure the presence of the reporter polynucleotide in the reporter host cells. Preferred selectable marker genes include, but are not limited to, G-418^R, mycophenolic acid resistance, DHFR, HSV-tk, and the like. Preferred reporter cassettes include sequences encoding a 15 protein which can be expressed on the cell surface of a metabolically active cell and detected without resulting in non-viability of the cell; preferably such proteins can be readily cleaved from the cell surface if desired so as to reduce background. A reporter polynucleotide may comprise tandem arrays of genetic elements at the discretion of the practitioner.

As used herein, the term "reporter host cell" refers to a eukaryotic cell, preferably a 20 mammalian cell, which harbors a reporter polynucleotide, a LBD-TRX expression cassette, and a CA-TRX expression cassette and/or a CR-TRX expression cassette. The reporter polynucleotide sequence may reside, in polynucleotide linkage, on the same polynucleotide as one or more of the expression cassette sequences, or may reside on a separate polynucleotide. The expression 25 cassettes and/or the reporter polynucleotides may be present as an extrachromosomal element (e.g., replicon), may be integrated into a host cell chromosome, or may be transiently transfected in non-replicable, non-integrated form. Preferably, the expression cassettes and reporter polynucleotide are both stably integrated into a host cell chromosomal location, either by nonhomologous integration or by homologous sequence targeting.

The term "transcriptional modulation" is used herein to refer to the capacity to either 30 enhance transcription or inhibit transcription of a structural sequence linked in *cis*; such enhancement or inhibition may be contingent on the occurrence of a specific event, such as stimulation with an inducer and/or may only be manifest in certain cell types. For example but not for limitation, 35 expression of a protein that prevents formation of an activated (e.g., ligand-bound) glucocorticoid receptor will alter the ability of a glucocorticoid-responsive cell type to modulate transcription of an glucocorticoid-responsive gene in the presence of glucocorticoid. This alteration will be manifest as

an inhibition of the transcriptional enhancement of the glucocorticoid-responsive gene that normally ensues following stimulation with glucocorticoids. The altered ability to modulate transcriptional enhancement or inhibition may affect the inducible transcription of a gene, such as in the just-cited example, or may effect the basal level transcription of a gene, or both. For example, a reporter 5 polynucleotide may comprise a glucocorticoid-inducible enhancer-promoter driving transcription of a sequence encoding a cell surface reporter protein. Such a reporter polypeptide may be transferred to a glucocorticoid-responsive cell line for use as a reporter host cell. Cloned sequences that silence expression of the cell surface reporter in cells cultured in the presence of glucocorticoids also may be (e.g., to reduce basal transcription and ensure detectable glucocorticoid inducibility). Numerous other 10 specific examples of transcription regulatory elements, such as specific enhancers and silencers, are known to those of skill in the art and may be selected for use in the methods and polynucleotide constructs of the invention on the basis of the practitioner's desired application. Literature sources and published patent documents, as well as GenBank™ and other sequence information data sources can be consulted by those of skill in the art in selecting suitable transcription regulatory elements and 15 other structural and functional sequences for use in the invention. Where necessary, a transcription regulatory element may be constructed by synthesis (and ligation, if necessary) of oligonucleotides made on the basis of available sequence information (e.g., GenBank sequences for a CD4 enhancer, HSV-TK promoter, or a SV40 early promoter).

20 As used herein, "linked" means in polynucleotide linkage (i.e., phosphodiester linkage) or polypeptide linkage, depending upon the context of usage. "Unlinked" means not linked to another polynucleotide or polypeptide sequence; hence, two sequences are unlinked if each sequence has a free 5' terminus and a free 3' terminus.

25 As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to 30 join two protein coding regions, contiguous and in reading frame. However, since enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous. A structural gene (e.g., a HSV tk gene) which is operably linked to a polynucleotide sequence corresponding to a transcriptional regulatory sequence of an endogenous gene is generally expressed 35 in substantially the same temporal and cell type-specific pattern as is the naturally-occurring gene.

Unless specified otherwise, the lefthand end of single-stranded polynucleotide sequences is the 5' end; the lefthand direction of double-stranded polynucleotide sequences is referred to as the 5' direction. The direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".

As used herein, the term "transcriptional regulatory sequence" refers to a 10 polynucleotide sequence or a polynucleotide segment which, when placed in operable linkage to a transcribable polynucleotide sequence, can produce transcriptional modulation of the operably linked transcribable polynucleotide sequence. A positive transcriptional regulatory element is a DNA sequence which activates transcription alone or in combination with one or more other DNA sequences. Typically, transcriptional regulatory sequences comprise a promoter, frequently an 15 enhancer, and may include other positive and/or negative regulatory elements as are known in the art or as can be readily identified by conventional transcription activity analysis (e.g., with "promoter trap" vectors, transcription rate assays, and the like). Often, transcriptional regulatory sequences include a promoter and a transcription factor recognition site (see, infra). The term often refers to a DNA sequence comprising a functional promoter and any associated transcription elements (e.g., 20 enhancer, CCAAT box, TATA box, SP1 site, etc.) that are essential for transcription of a polynucleotide sequence that is operably linked to the transcription regulatory region.

The term "transcriptional enhancement" is used herein to refer to functional property 25 of producing an increase in the rate of transcription of linked sequences that contain a functional promoter.

As used herein, the term "transcriptional unit" or "transcriptional complex" refers to a polynucleotide sequence that comprises a structural gene (exons), a cores-acting linked promoter and other cores-acting sequences necessary for efficient transcription of the structural sequences, distal 30 regulatory elements necessary for appropriate tissue-specific and developmental transcription of the structural sequences, and additional cores sequences important for efficient transcription and translation (e.g., polyadenylation site, mRNA stability controlling sequences).

As used herein, a "transcription factor recognition site" and a "transcription factor 35 binding site" refer to a polynucleotide sequence(s) or sequence motif(s) which are identified as being sites for the sequence-specific interaction of one or more transcription factors, frequently taking the form of direct protein-DNA binding. Typically, transcription factor binding sites can be identified by

DNA footprinting, gel mobility shift assays, and the like, and/or can be predicted on the basis of known consensus sequence motifs, or by other methods known to those of skill in the art. For example and not to limit the invention, eukaryotic transcription factors include, but are not limited to: NFAT, AP1, AP-2, Sp1, OCT-1, OCT-2, OAP, NF B, CREB, CTF, TFIIA, TFIIB, TFIID, Pit-1, C/EBP, SRF (Mitchell 5 PJ and Tijan R (1989) *Science* 245: 371). For purposes of the invention, steroid receptors, steroid superfamily receptors, other nuclear receptors, RNA polymerases, and other proteins that interact with DNA in a sequence-specific manner and exert transcriptional regulatory effects are considered transcription factors.

10. As used herein, the term "functionally expressed" refers to a coding sequence which is transcribed, translated, post-translationally modified (if relevant), and positioned in a cell such that the protein provides the desired function. With reference to a reporter cassette, functional expression generally means production of a sufficient amount of the encoded cell surface reporter protein to provide a statistically significant detectable signal to report ligand-induced transcriptional effect of a 15 reporter polynucleotide.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, an array of spatially localized compounds (e.g., a VLSIPS peptide array, polynucleotide array, and/or combinatorial small molecule array), a biological macromolecule, a 20 bacteriophage peptide display library, a bacteriophage antibody (e.g., scFv) display library, a polysome peptide display library, or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents are evaluated for potential activity as nuclear receptor agonist agents by inclusion in screening assays of the methods described herein or the like. Agents are evaluated for potential activity as specific nuclear receptor agonists by 25 inclusion in screening assays described hereinbelow. Agents may act directly, by serving as a ligand to the LBD of the LBD-TRX fusion protein, and/or they may act indirectly, by producing a second messenger which activates the LBD (e.g., a kinase which phosphorylates the LBD, a second hormone which is a ligand of the LBD, and the like). A "test agent" is an agent which is being evaluated by the methods of the invention to determine whether it possesses agonist activity, antagonist activity, or no 30 activity with regard to the LBD of the nuclear receptor.

As used herein, the term "test ligand" is an agent which has chemical properties consistent with the agent serving as a ligand of a predetermined nuclear receptor LBD with an affinity of at least about 1×10^6 M⁻¹. Typically, these properties can include small size (e.g., MW less than 35 3,000 Daltons), hydrophobicity, structural similarity to known ligands of the receptor LBD, and/or predicted interaction with an LBD binding pocket based on computer modeling.

As used herein, the term "agonist" refers to an agent which produces activation of a nuclear receptor and/or which, when contacted with a nuclear receptor signal transduction system of the invention, produces a substantial increase in binding of one or more coactivator protein(s) to an LBD-TRX fusion protein, and/or relieves binding of one or more corepressors to the LBD-TRX fusion protein.

As used herein, the term "antagonist" refers to an agent which opposes the agonist activity of a known agonist of the nuclear receptor LBD, or enhances or stabilizes binding of a corepressor protein to a LBD-TRX protein and/or inhibits binding of one or more coactivators to the LBD-TRX fusion protein.

"Physiological conditions" as used herein refers to temperature, pH, ionic strength, viscosity, and like biochemical parameters that are compatible with a viable organism, and/or that typically exist intracellularly in a viable cultured mammalian cell, particularly conditions existing in the nucleus of said mammalian cell. For example, the intranuclear or cytoplasmic conditions in a mammalian cell grown under typical laboratory culture conditions are physiological conditions. Suitable in vitro reaction conditions for in vitro transcription cocktails are generally physiological conditions, and may be exemplified by a variety of art-known nuclear extracts. In general, in vitro physiological conditions can comprise 50-200 mM NaCl or KCl, pH 6.5-8.5, 20-45 C and 0.001-10 mM divalent cation (e.g., Mg⁺⁺, Ca⁺⁺); preferably about 150 mM NaCl or KCl, pH 7.2-7.6, 5 mM divalent cation, and often include 0.01-1.0 percent nonspecific protein (e.g., BSA). A non-ionic detergent (Tween, NP-40, Triton X-100) can often be present, usually at about 0.001 to 2%, typically 0.05-0.2% (v/v). Particular aqueous conditions may be selected by the practitioner according to conventional methods. For general guidance, the following buffered aqueous conditions may be applicable: 10-250 mM NaCl, 5-50 mM Tris HCl, pH 5-8, with optional addition of divalent cation(s), metal chelators, nonionic detergents, membrane fractions, antifoam agents, and/or scintillants.

As used herein, the terms "label" or "labeled" refer to incorporation of a detectable marker, e.g., a radiolabeled amino acid or a recoverable label (e.g. biotinyl moieties that can be recovered by avidin or streptavidin) or an epitope tag or linked catalytic activity. Recoverable labels can include covalently linked polynucleobase sequences that can be recovered by hybridization to a complementary sequence polynucleotide. Various methods of labeling polypeptides and polynucleotides are known in the art and may be used. Examples of labels include, but are not limited to, the following: radioisotopes (e.g., ³H, ¹⁴C, ³⁵S, ¹²⁵I, ¹³¹I), fluorescent or phosphorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, galactosidase, luciferase, alkaline phosphatase), biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for antibodies,

transcriptional activator polypeptide, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths, e.g., to reduce potential steric hindrance. A "labeled antibody" can be a primary antibody having an attached detectable label or a primary antibody which can be detected by a secondary antibody having an attached detectable label.

5

As used herein, the term "statistically significant" means a result (i.e., an assay readout) that generally is at least two standard deviations above or below the mean of at least three separate determinations of a control assay readout and/or that is statistically significant as determined by Student's t-test or other art-accepted measure of statistical significance.

10

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Generally, the nomenclature used hereafter and the laboratory procedures in cell culture, molecular genetics, and nucleic acid chemistry and hybridization described below are those well known and commonly employed in the art. Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, cell culture, and transgene incorporation (e.g., electroporation, microinjection, lipofection). Generally enzymatic reactions, oligonucleotide synthesis, and purification steps are performed according to the manufacturer's specifications. The techniques and procedures are generally performed according to conventional methods in the art and various general references which are provided throughout this document, as well as: Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.; and Berger and Kimmel, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques (1987), Academic Press, Inc., San Diego, CA, which are incorporated herein by reference. The procedures are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Oligonucleotides can be synthesized on an Applied Bio Systems oligonucleotide synthesizer according to specifications provided by the manufacturer.

30

All sequences referred to herein by GenBank database file designation (e.g., GenBank: Humanct4a) or otherwise obtainable by routine search of a publicly-available sequence database or scientific publications and are incorporated herein by reference and are publicly available, such as by reconstruction of the sequence by overlapping oligonucleotides or other means.

35

All publications referred to are incorporated herein for all purposes, including as if the publications, including any diagrams or figures, were reproduced herein.

Overview

In general, the invention encompasses methods, polynucleotide constructs, and host cells which are employed for generating and screening agents for the purpose of identifying agents which are agonists or antagonists of a predetermined nuclear receptor having a LBD which can, in a first state unbound by agonist ligand, remain substantially unbound with regard to a coactivator protein, typically a protein containing at least one -LXXLL- motif, and, in a second state bound by agonist ligand, bind to said coactivator protein. In general, the methods employ a LBD-TRX fusion protein to detect agonist ligands. Agonist ligands produce a conformational change in the LBD-TRX, thereby activating a binding moiety that allows binding to a coactivator protein (or dissociation of a corepressor protein), said binding moiety which is otherwise substantially repressed by the unliganded LBD. The result of the ligand-induced LBD alteration causes binding of a CA-TRX to form a transcriptionally active complex which can drive transcription of the reporter polynucleotide to produce functional expression of the reporter cassette.

The invention separates the function of ligand binding from other functions of transcription factors, coupling ligand binding to cofactor-binding activity which can be assessed by a particularly advantageous means of measuring these inter-protein interactions.

Wagner et al. (1998) *Mol. Cell. Biol.* **18**: 1369, Horwitz (1996) *op.cit*, Glass et al. (1997) *op.cit*, and Krey et al. (1997) *Mol. Endocrin.* **35**: 779, describe methods for identifying LBD interactions with coactivators and corepressors in a ligand-dependent manner.

The present invention provides methods and compositions provide a means for highly sensitive, reliable, and automatable screening a bank of agents to identify agonist agents and antagonists which are able to conformationally activate the LBD of a nuclear receptor.

Nuclear Receptor LBDs

Nuclear receptors suitable for providing an LBD for the method are those receptors which are localized in the nucleus and/or can translocate to the nucleus upon ligand binding. Such nuclear receptors which have a regulable domain which represses an adjacent, or closely linked, functional domain, wherein such repression is substantially relieved upon activation of the regulable domain by an agonistic stimulus, such as by binding of an agonist ligand, are suitable for use. Often, the regulable domain binds a known ligand, such as a steroid hormone, retinoid, or other generally hydrophobic small molecule ligand. Most usually, ligand binding and domain activation occurs in a stereospecific manner which is selective for particular ligand geometries and structural features. Ribiero RC et al. (1995) *op.cit* provides a general overview of some such nuclear receptors. Glass et al. (1997) *op.cit* also provides examples of nuclear receptors.

The list of known nuclear receptors includes, but is not limited to the steroid receptor superfamily (e.g., estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), glucocorticoid receptor (GR), retinoic acid receptor ("RAR"), retinoid-X receptor ("RXR"), vitamin D receptor ("VDR"), peroxisome proliferator activation receptor ("PPAR"; such as for example PPAR₁, PPAR₂, and PPAR₃), thyroid hormone receptor ("TR"), farnesoid receptor ("FXR"), insect ecdysone receptor ("EcR"), retinoid-Z receptor ("RZR"), and other related receptor homolog genes as is known in the art and/or can be determined by a skilled artisan by computerized homology searching of public nucleic acid and protein sequence databases. Green et al (1995) Mutat. Res. 333:101 discloses the peroxisome proliferator activation receptor (PPAR). Greiner et al. (1996) PNAS 93:10105, Carlberg et al. (1994) Mol. Endocrinol. 8:757, Medvedev et al. (1996) Gene 181:199, and Schrader et al. (1996) J. Biol. Chem. 271:19732, disclose the RZR receptor. Kephart et al. (1996) Mol. Endocrinol. 10:408 discloses the vitamin-D receptors (VDRs). Kozak et al. (1996) Mamm. Genome 7:164 discloses the farnesoid receptor (FXR). The sequences of the steroid receptor superfamily members can be readily obtained from public sequence databases and published scientific and patent literature. The identification of the ligand binding domain (LBD) for each member is either published or can be determined by a skilled artisan on the basis of sequence identity and structural homology to known steroid superfamily receptors. Routine assay to determine the exact boundaries, if necessary, of the LBD of a given nuclear receptor can be performed by straightforward deletion analysis and measurement of ligand binding and/or retention of a fragment to confer ligand-induced derepression of a linked SSR.

LBD-TRX Fusion Proteins

Polypeptides encoding LBD-TRX fusion proteins which are ligand-activatable transcription partners with complementing hybrid CA-TRX or CR-TRX fusion proteins can be expressed from a polynucleotide encoding a protein comprising a LBD of a nuclear receptor in polypeptide linkage to a TRX, optionally separated by a polypeptide spacer of from 1 to about 25 amino acids of a non-interfering sequence.

In aspects of the invention, the LBD portion of the LBD-TRX fusion protein is a mutein comprising at least one mutation as compared to the LBD sequence of the naturally occurring nuclear receptor from which the LBD was derived.

Kellendonk et al. (1996) Nucleic Acids Res. 24:1404, Zhang et al. (1996) Nucleic Acids Res. 24:543, and Metzger et al. (1995) PNAS 92:6991, report fusions of hormone-binding domains to Cre recombinase to produce a hormone-inducible Cre recombinase. Logie C and Stewart AF (1995) op.cit. Report fusion of a hormone-responsive domain to FLP recombinase. Kolb AF and Siddell SG (1996) Gene 183:1 also report enzymatically active fusions of the Cre recombinase. Thus,

skilled artisans are able to identify suitable portions of nuclear receptors for obtaining the necessary encoding segments for the LBD portions of a LBD-TRX. For convenience, practitioners can refer to such publications for additional guidance in selecting LBD sequences.

Reporter Polynucleotides

A reporter polynucleotide unit comprises a transcriptional regulatory sequence operably linked to a structural sequence that encodes reporter. The reporter polynucleotide may comprise one or more tandem repeats of this basic format, so as to amplify the signal-to-noise ratio in cells in which a LBD-TRX is activated by ligand. In a variation, at least two repeats of the reporter polynucleotide unit are present and linked by a spacer sufficient to reduce the frequency of inter-unit site-specific recombination which could reduce signal. A sufficient space is believed to be about at least 100 to 250 nucleotides of non-interfering sequence, and can be readily calibrated empirically by varying the lengths of spacer polynucleotide sequence and determining optimal lengths for maximal reporter gene expression. Spacers of less than 100 nucleotides or more than 250 nucleotides can be used at the discretion of the practitioner. The reporter polynucleotide may be linked to the LBD-TRX (CA-TRX and/or CR-TRX) expression cassette or it may be unlinked.

Reporter Proteins

The reporter genes used in the art include the conventional reporters of transcription (e.g., -gal, luciferase, chloramphenicol acetyltransferase(CAT), selectable drug markers (neo, gpt, tk), alkaline phosphatase, and green fluorescent protein).

Reporter enzymes can be natural full-length proteins or enzymatically functional fragments and amino acid sequence variants of the such. For example, some enzymes have a single domain that in isolation can confer enzymatic activity.

Suitable reporter genes for use in the invention include chloramphenicol acetyl transferase (CAT) (Alton & Vapnek (1979), *Nature* 282:864-869); luciferase (luc); alkaline phosphatase (Toh et al. (1989), *Eur. J. Biochem.* 182:231-238); and -galactosidase. Firefly luciferase is particularly suitable (deWet (1986) *Methods in Enzymology* 133:3-14; de Wet et al. (1985) *Proc. Natl. Acad. Sci.* 82:7870-7873; deWet et al. (1987) *Mol. Cell. Biol.* 7:725-737). Four species of firefly from which the DNA encoding luciferase may be derived, are the Japanese GENJI and HEIKE fireflies Luciola cruciata and Luciola lateralis, the East European Firefly Luciola mingrellica and the North American firefly (Photinus pyralis) (commercially available from Promega as the plasmid pGEM). The glow-worm Lampyris noctiluca is a further source of luciferase gene having 84% sequence identity to that of Photinus pyralis. The sequences obtaining reporter enzymes can be genomic, cDNA, a hybrid of the two, or synthetic. The advantages of the present invention are realized most fully for reporter enzymes having substrates to which a eukaryotic cell plasma membrane is substantially impermeable. That is such a

substrate is not taken up by such cells in sufficient amounts to generate a readily detectable metabolic product that distinguishes cells expressing a reporter enzyme from other cells. Such is the case for substrates of luciferase, alkaline phosphatase and beta-galactosidase.

5 One type of reporter protein comprises a sequence of a naturally-occurring cell surface protein (e.g., human CD8, membrane-bound μ immunoglobulin, glycophorin A) or may be a fusion protein (e.g., a β -galactosidase/ β -glutamyl transpeptidase fusion protein). Preferably, the cell surface reporter protein either is a protein not normally expressed on the host cells or is heterologous (i.e., from a different species), so that the cell surface reporter can be discriminated, for example with
10 a species-specific antibody, from cell surface proteins that naturally occur on the host cell surface. More preferably, the cell surface reporter protein is both heterologous and a protein not normally expressed on the host cell. For example, a mouse hepatoma cell does not normally express a significant amount of CD8 protein, a protein characteristic of cytotoxic T lymphocytes. With reference to the mouse hepatoma cell, a cell surface reporter comprising a human CD8 protein is both
15 heterologous and a protein not normally expressed on the cell type (i.e., hepatocyte). A structural sequence of a cell surface reporter may comprise a polynucleotide sequence encoding a fusion protein having a segment that does not occur naturally in eukaryotes (e.g., a bacterial sequence such as β -galactosidase) fused, in correct reading frame, into an extracellular portion of a transmembrane protein (e.g., human β -glutamyltranspeptidase heavy subunit; GenBank: HUMGgt, HUMGgtx;
20 Goodspeed et al. (1989) Gene 76: 1, incorporated herein by reference).

Host cells

Host cells typically include mammalian cells and other types of eukaryotic cells, such as yeast, insect cell, and fungi. Immortalized host cell cultures amenable to transfection and *in vitro* cell culture and of the kind typically employed in genetic engineering are preferred (e.g., HeLa cells, KB cells, JW-2 cells, Detroit 6 cells, COS cells, CV-1 cells, VERO cells, and NIH-3T3 cells).
25 Embryonic cell used for generating transgenic animals are also suitable (e.g., zygotes and embryonic stem cells). The cell type should be capable of expressing the reporter construct encoding a fusion protein. Host cells are typically mammalian cells, and most preferably are mammalian cell lines, such as HepG2, COS-7, CHO, HeLa, Hepa, NIH3T3, EBV-immortalized lymphocytes, or other cell lines available in the art. Suitable cell lines and cell strains may be obtained from several sources, including the American Type Culture Collection ("ATCC Catalog of Cell Lines and Hybridomas", American Type Culture Collection, Rockville, MD, which is incorporated herein by reference).
30 Alternatively, it is possible to practice the invention with primary cell explants, such as lymphocytes, hematopoietic stem cells, and primary hepatocytes.
35

Various host cells may be selected in the discretion of the practitioner. The selection of a host cell generally is based upon the competence of the cell to support transcription from the transcription regulatory sequence of the reporter polynucleotide.

5 A host cell which harbors a reporter polynucleotide and fusion protein expression cassettes is a reporter host cell. A reporter host cell may harbor the reporter polynucleotide in any of several formats, including: as a replicable episome, as a nonhomologously integrated transgene, as a homologously targeted sequence, as an artificial chromosome, or as a transient non-replicable polynucleotide. A reporter host cell can be readily identified as such by the detectable presence of a 10 reporter polynucleotide, which comprises a transcription regulatory sequence operably linked to a reporter sequence and which, when considered as a unitary polynucleotide sequence spanning both structural and regulatory elements, is not present in the host cell genome as a naturally-occurring polynucleotide sequence.

15 Specific protein-protein interactions are fundamental to most cellular and organismal functions. Polypeptide interactions are involved in formation of functional transcription complexes, signal transduction pathways, cytoskeletal organization (e.g., microtubule polymerization), polypeptide hormone receptor-ligand binding, organization of multi-subunit enzyme complexes, and the like.

20 Two-Hybrid Interaction Systems

Investigation of protein-protein interactions under physiological conditions has been problematic. Considerable effort has been made to identify proteins that bind to proteins of interest. Typically, these interactions have been detected by using co-precipitation experiments in which an antibody to a known protein is mixed with a cell extract and used to precipitate the known protein and 25 any proteins which are stably associated with it. This method has several disadvantages, such as: (1) it only detects proteins which are associated in cell extract conditions rather than under physiological, intracellular conditions, (2) it only detects proteins which bind to the known protein with sufficient strength and stability for efficient co-immunoprecipitation, and (3) it fails to detect associated proteins which are displaced from the known protein upon antibody binding. For these reasons and others, 30 improved methods for identifying proteins which interact with a known protein have been developed.

Two-Hybrid Systems

One approach has been to use a so-called "two-hybrid" system to identify polypeptide sequences which bind to a predetermined polypeptide sequence present in a fusion protein (Chien et al. (1991) Proc. Natl. Acad. Sci. (USA) 88: 9578). This approach identifies protein-protein interactions 35 *in vivo* through reconstitution of a transcriptional activator (Fields S and Song O (1989) Nature 340: 245), the yeast Gal4 transcription protein. The method is based on the properties of the yeast Gal4

protein, which consists of separable domains responsible for DNA-binding and transcriptional activation. Polynucleotides encoding two hybrid proteins, one consisting of the yeast Gal4 DNA-binding domain fused to a polypeptide sequence of a known protein and the other consisting of the Gal4 activation domain fused to a polypeptide sequence of a second protein, are constructed and introduced into a yeast host cell. Intermolecular binding between the two fusion proteins reconstitutes the Gal4 DNA-binding domain with the Gal4 activation domain, which leads to the transcriptional activation of a reporter gene (e.g., *lacZ*, *HIS3*) which is operably linked to a Gal4 binding site. Typically, the two-hybrid method is used to identify novel polypeptide sequences which interact with a known protein (Silver SC and Hunt SW (1993) *Mol. Biol. Rep.* 17: 155; Durfee et al. (1993) *Genes Devel.* 7: 555; Yang et al. (1992) *Science* 257: 680; Luban et al. (1993) *Cell* 73: 1067; Hardy et al. (1992) *Genes Devel.* 6: 801; Bartel et al. (1993) *Biotechniques* 14: 920; and Vojtek et al. (1993) *Cell* 74: 205). However, variations of the two-hybrid method have been used to identify mutations of a known protein that affect its binding to a second known protein (Li B and Fields S (1993) *FASEB J.* 7: 957; Lalo et al. (1993) *Proc. Natl. Acad. Sci. (USA)* 90: 5524; Jackson et al. (1993) *Mol. Cell. Biol.* 13: 2899; and Madura et al. (1993) *J. Biol. Chem.* 268: 12046). Two-hybrid systems have also been used to identify interacting structural domains of two known proteins (Bardwell et al. (1993) *med. Microbiol.* 8: 1177; Chakraborty et al. (1992) *J. Biol. Chem.* 267: 17498; Staudinger et al. (1993) *J. Biol. Chem.* 268: 4608; and Milne GT and Weaver DT (1993) *Genes Devel.* 7: 1755) or domains responsible for oligomerization of a single protein (Iwabuchi et al. (1993) *Oncogene* 8: 1693; Bogerd et al. (1993) *J. Virol.* 67: 5030). Variations of two-hybrid systems have been used to study the *in vivo* activity of a proteolytic enzyme (Dasmahapatra et al. (1992) *Proc. Natl. Acad. Sci. (USA)* 89: 4159). Alternatively, an *E. coli*/BCCP interactive screening system (Germino et al. (1993) *Proc. Natl. Acad. Sci. (U.S.A.)* 90: 933; Guarente L (1993) *Proc. Natl. Acad. Sci. (U.S.A.)* 90: 1639) can be used to identify interacting protein sequences (i.e., protein sequences which heterodimerize or form higher order heteromultimers).

Each of these two-hybrid methods rely upon a positive association between two Gal4 fusion proteins thereby reconstituting a functional Gal4 transcriptional activator which then induces transcription of a reporter gene operably linked to a Gal4 binding site. Transcription of the reporter gene produces a positive readout, typically manifested either (1) as an enzyme activity (e.g., galactosidase) that can be identified by a colorimetric enzyme assay, or (2) as enhanced cell growth on a defined medium (e.g., *HIS3*). Thus, these methods are suited for identifying a positive interaction of polypeptide sequences, but are poorly suited for identifying agents or conditions which alter (e.g., inhibit) intermolecular association between two polypeptide sequences.

Reverse Two-Hybrid Systems

A general method is provided, referred to herein as a reverse two-hybrid method, wherein agents which disrupt an intermolecular association between two interacting polypeptides (LBD and either a CA or CR domain) thereby generate a selectable and/or detectable readout (e.g., 5 complementation of an auxotrophic phenotype, expression of a detectable reporter molecule, and the like). Typically, a reverse two-hybrid method produces a positive readout under conditions wherein an agent blocks or otherwise inhibits the intermolecular binding of the interacting polypeptides. A positive readout condition is generally identified as one or more of the following detectable conditions: (1) an increased transcription rate of a predetermined reporter gene, (2) an increased concentration or 10 abundance of a polypeptide product encoded by a predetermined reporter gene, typically such as an enzyme which can be readily assayed *in vivo*, and/or (3) a selectable or otherwise identifiable phenotypic change in an organism (e.g., yeast) harboring the reverse two-hybrid system. Generally, a 15 selectable or otherwise identifiable phenotypic change that characterizes a positive readout condition confers upon the organism either: a selective growth advantage on a defined medium, a mating phenotype, a characteristic morphology or developmental stage, drug resistance, or a detectable enzymatic activity (e.g., β -galactosidase, luciferase, alkaline phosphatase, and the like). In this manner, it is possible to efficiently identify agents (including but not limited to polypeptides, small 20 molecules, and oligonucleotides) which inhibit intermolecular binding between two predetermined interacting polypeptides.

20

In an aspect of the invention, a reverse two-hybrid system is composed of: (1) a first hybrid protein (e.g., an LBD-TRX), (2) a second hybrid protein (e.g., a CA-TRX or a CR-TRX) which binds to the first hybrid protein under control conditions (e.g., physiological conditions in the absence of agent), (3) a relay (or signal inverter) gene which is efficiently expressed as a consequence of the 25 first hybrid protein and the second hybrid protein being functionally bound to each other, and (4) a reporter gene which is efficiently expressed when the product of the relay (or signal inverter) gene is substantially absent and is either poorly expressed or not expressed when the relay (or signal inverter) gene product is efficiently expressed. The first hybrid protein and second hybrid protein bind to each other through interacting polypeptide segments (i.e., a portion of the first hybrid protein preferentially 30 binds to a portion of the second hybrid protein forming a heterodimer or higher order heteromultimer comprising the first and second hybrid proteins; said binding portions of each hybrid protein are termed "interacting polypeptide segments").

The first hybrid protein comprises: (1) a first interacting polypeptide sequence (LBD) 35 in polypeptide linkage with (2) a DNA-binding domain of a transcriptional activator protein or other DNA binding protein (e.g., a repressor). The second hybrid protein comprises: (1) a second interacting polypeptide sequence (CA or CR), capable of forming an intermolecular association with

the first interacting polypeptide sequence under control conditions (e.g., physiological conditions and absence of agent) in polypeptide linkage with (2) an activation domain of a transcriptional activator protein, whereby intermolecular binding between the first hybrid protein and the second hybrid protein (via the interacting polypeptide sequences) thereby unites the DNA-binding domain of the first hybrid protein with the activation domain of the second generating a transcriptional activator function. Generally, the first hybrid protein and the second hybrid protein are encoded by polynucleotides which are constitutively expressed in a host organism (e.g., a eukaryotic or prokaryotic cell; or multicellular organism).

10 The relay gene (alternatively termed the signal inverter gene) is operably linked to a transcriptional regulatory sequence (a "relay transcriptional regulatory sequence") which is positively regulated by the transcriptional activator that is formed by the intermolecular binding of the first hybrid protein to the second hybrid protein. Hence, when the first hybrid protein binds to the second hybrid protein (via the interacting polypeptide sequences), the transcriptional activator formed thereby binds 15 to a transcriptional regulatory sequence operably linked to the relay gene and enhances the net transcription of the relay gene. The relay gene encodes a protein that represses transcription of a reporter gene. Thus, when the first and second hybrid proteins are functionally bound to each other, the relay gene is expressed and thereby represses transcription of the reporter gene(s). In an embodiment, such relay proteins are of the type often referred to in the art as "negative regulators of 20 transcription". In an embodiment of the invention, the relay gene is a negative regulator of transcription in yeast; for example but not limitation the *GAL80* gene can serve as a relay gene in yeast. In embodiments where host organisms are employed to harbor the reverse two-hybrid system, the relay gene is often a gene which naturally occurs in the germline DNA of the host organism species, and frequently can be an endogenous germline gene, or alternatively may be introduced into 25 the host organism as exogenous DNA, typically into a host genome that lacks the corresponding functional endogenous gene (e.g., a "knockout background").

30 The reporter gene is operably linked to a transcriptional regulatory sequence ("reporter transcriptional regulatory sequence") which is negatively regulated by the gene product of the relay gene and which is induced in the absence of the relay gene product. Thus, transcription of the reporter gene is repressed in control conditions (e.g., physiological conditions in the absence of agent) wherein the two-hybrid proteins bind to each other and form a transcriptional activator that increases transcription of the relay gene. Generally, the relay gene product either binds to the transcriptional regulatory sequence operably linked to the reporter gene, or binds to a transcription 35 protein that binds to the transcriptional regulatory sequence operably linked to the reporter gene. The net transcription rate of the reporter gene is reduced (or completely blocked) as a consequence of the relay gene product binding to the reporter gene transcriptional regulatory sequence and/or to a

transcription protein required for constitutive expression of the reporter gene. Any of a variety of reporter genes that produce a positive readout can be used. For example and not limitation, suitable reporter genes are those which (1) confer a selectable phenotype to cells in which the reporter gene is efficiently expressed, and/or (2) encode a gene product (e.g., enzyme) which is conveniently detected such as by *in situ* assay or the like. Suitable genes which confer a selectable phenotype are exemplified by, but not limited to, genes which complement auxotrophic mutations in a host organism (e.g., yeast *HIS3*), genes which encode drug resistance (e.g., *neo*^R), genes which induce cell proliferation, and other genes whose expression confers a selective growth advantage. Suitable genes which encode a gene product which is conveniently detected *in situ* are exemplified by, but not limited to, β -galactosidase (e.g., *E. coli lacZ*), luciferase, alkaline phosphatase, horseradish peroxidase, and the like.

The invention provides polynucleotides encoding a first hybrid protein and a second hybrid protein. Such polynucleotides encode a DNA-binding domain or activation domain of a transcriptional activator and conveniently can have a cloning site for adjacent insertion, in reading frame, of polynucleotide sequences encoding one or more interacting polypeptide sequence(s). Typically, a first polynucleotide will encode a first hybrid protein composed of a first predetermined interacting polypeptide sequence and a DNA-binding domain of a transcriptional activator; a second polynucleotide will encode a second hybrid protein composed of a second predetermined interacting polypeptide sequence and an activation domain of a transcriptional activator, wherein the DNA-binding domain of the first hybrid protein can reconstitute with the activation domain and form a functional transcriptional activator. Often, the DNA-binding domain and the activation domain of the hybrid protein pair are derived from the same naturally occurring transcription activator (e.g., Gal4). However, those of skill in the art can select DNA-binding domains and activation domains from distinct transcription activators which can reconstitute to form a functional transcriptional activator which does not occur in nature (e.g., a DNA-binding domain of the bacterial *lexA* protein can be used in conjunction with a transcriptional activator from the viral protein, VP16; Vojtek et al. (1993) *op.cit.*). Transcription and translation of such a polynucleotide produces a hybrid (or fusion) protein composed of an interacting polynucleotide segment and a DNA-binding domain or activation domain of a transcriptional activator.

The invention also provides polynucleotides which comprise a transcriptional regulatory sequence operably linked to a relay (or signal inverter) gene. A relay (or signal inverter) gene encodes a protein that inhibits or otherwise represses expression (typically transcription) of a predetermined reporter gene. Most usually, a relay protein is a negative regulator of transcription for a predetermined gene or gene subset. In an embodiment, the relay protein is a transcription repressor protein that binds to a polynucleotide sequence and thereby inhibits transcription of a *cis*-linked and

operably linked sequence. In an alternative embodiment, the relay protein binds to a protein that is a positive regulator of transcription of a predetermined gene or gene subset, and as a consequence of binding thereby inhibits the transcriptional activity of the positive regulator. One variety of such a relay protein binds to and blocks the activation domain(s) of transcriptional activators. Although a variety of suitable relay proteins are apparent to those of skill in the art, this category of relay protein can be exemplified by the mammalian *mdm2* oncoprotein which binds the transactivation domain of the tumor suppressor protein *p53*, and the yeast Gal80 protein which binds and inactivates the activation domain of Gal4. In an embodiment, the relay protein comprises a mutation, addition, or deletion that reduces the stability of the relay protein *in vivo* as compared to the naturally occurring cognate relay protein.

10 Relay proteins can be referred to as signal inverter proteins, as they serve to invert a positive transcriptional signal (the reconstitution of a functional transcriptional activator by binding of the two hybrid proteins) into a negative transcriptional signal, which reduces transcription of a predetermined reporter gene. Generally, a polynucleotide encoding a relay protein is operably linked to a relay transcriptional regulatory sequence that produces transcription of the relay gene dependent upon

15 functional reconstitution of the DNA-binding domain and activation domain of the two hybrid proteins. For example and not limitation, such a relay transcriptional regulatory sequence can comprise a promoter and a polynucleotide sequence comprising one or more site(s) which bind(s) a reconstituted functional transcriptional activator formed by association of the two hybrid proteins; for example, if the two hybrid transcriptional activator comprises a *lexA* DNA-binding domain, the relay transcriptional

20 regulatory sequence operably linked to the relay gene can comprise one or more *lexA* binding site sequences, arrayed in tandem.

Other aspects of two-hybrid systems are described in U.S. Patent 5,525,490, incorporated herein by reference for all purposes.

25

Other Aspects

The invention provides a method for identifying agonist ligands of a predetermined nuclear receptor. The method comprises:

30 forming agent-treated host cells by contacting (1) a test agent with (2) a population of reporter cells;

35 incubating the agent-treated host cell under incubation conditions for a suitable incubation period sufficient for distribution of the test agent to the nucleus to allow for formation, if any, of a liganded complex comprising a LBD-TRX fusion protein and a CA-TRX (or a CR-TRX) fusion protein; and,

identifying as an agonist ligand a test agent which produces a statistically significant increase in detectable expression of the reporter protein in the population of agent-treated host cells as compared to a reference population of untreated host cells incubated under substantially identical conditions and lacking said test agent.

5

In an aspect of the method, the test agent consists of at least one species of small molecule (M.W. <3,000 Daltons). In an aspect of the method, the test agent is a lipophilic compound.

In an embodiment, the test agent is a steroid, retinoid, thyroxine analog, vitamin D derivative, or polycyclic aromatic hydrocarbon. In an embodiment, untreated host cells are contacted with vehicle or 10 a known inert substance in place of the test agent. Often, a spacer polypeptide sequence of 1 to about 100 amino acids of a non-interfering amino acid sequence (which may be selected by the artisan and determined empirically without necessitating undue experimentation) is in polypeptide linkage between the LBD segment and the TRX segment and/or between the CA (or CR) segment and its linked TRX segment, such as to reduce potential steric hindrance.

15

In an aspect, the method may be used to rank-order the efficacy and/or potency (or other pharmacological property) of a collection of test agents for agonist or antagonist activity relative to a predetermined nuclear receptor. A collection (or library) of test agents can be screened, either by parallel screening of individual test agent species or in pools of test agents having related structural

20 features, to determine the ability of each test agent species or pool thereof to elicit a dose-dependent and/or time-dependent activation of the LBD-TRX in a population of reporter host cells. The method typically employs a population of reporter host cells which are subdivided into a plurality of subpopulations that are cultured under substantially identical conditions, such as for example in the wells of a multiwell culture vessel (e.g., 96 well microtitre dish), forming a collection of culture vessels 25 (e.g., wells) each having an approximately equivalent reporter host cell subpopulation exposed to substantially identical conditions. To each culture vessel (e.g., well) is added a predetermined amount or concentration of a test agent or a pool of test agents, such that for a given test agent species or pool, a plurality of dosage levels or concentrations are represented in the collection of culture vessels.

For example and not limitation, a 96-well plate may have each row representing a distinct test agent

30 species and each column representing a series of predetermined dosages or concentrations (or predetermined dilution ratios of a stock test agent solution of unknown concentration). Following addition of the test agent or pool, the culture vessels containing the reporter host cells exposed to the

test agent or pool are incubated under suitable incubation conditions (e.g., conventional cell culture conditions) for a time period sufficient to produce activation of a nuclear receptor of the type from whence the LBD portion of the LBD-SSR in the reporter host cells was obtained. Following or during the incubation time period, the expression of cell surface reporter protein is detected from each culture vessel and compared to the expression level, if any, of the cell surface reporter in a parallel culture vessel containing reporter host cells cultured under substantially identical conditions but lacking a test agent, but in some embodiments administered the vehicle used to deliver the test agent(s), as a control to establish background reporter expression. If desired, the level of cell surface reporter expression in each culture vessel can be detected and quantified at a plurality of time points, such as

10 to determine a time course of activity for each test agent species or pool. By comparing the amount of cell surface reporter expression in each culture vessel, a dose-response curve (e.g., wherein expression of the cell surface reporter is the response) and/or activation time curve can be calculated for each test agent or pool to determine the pharmacological profile of each test agent or pool. Exemplary pharmacological parameters can include, for example, ED₅₀, binding constants, latency of

15 activation, and the like, among others. Each test agent species or pool can be rank-ordered relative to other test agents or pools evaluated under substantially identical conditions on the basis of the dose-response data thus obtained, and preferred test agents having desired pharmacological parameters can be identified thereby.

20 The invention also provides kits comprising an expression polynucleotide encoding a LBD-SSR fusion, a reporter polynucleotide of the invention, and, optionally, a suitable host cell, and optionally, instructions for use. In a variation, the kit also comprises a second polynucleotide which confers a selectable phenotype on host cells in which said second polynucleotide has undergone site-specific recombination. In an embodiment, the kit comprises reporter cells suitable for use in test

25 agent screening assays to identify agonists and/or antagonists for ligands of the predetermined nuclear receptor.

Although the present invention has been described in some detail by way of illustration for purposes of clarity of understanding, it will be apparent that certain changes and

30 modifications may be practiced within the scope of the claims. The following experimental examples are offered for illustration and are not intended to limit the invention in any way.

EXPERIMENTAL EXAMPLESOverview

The use of nuclear receptor:coactivator interactions as a means for identifying and categorizing nuclear receptor ligands to be used in high-throughput screening was evaluated. A direct 5 interaction assay suitable for in vitro use with enzymatic readout (ELISA) was constructed using fusion proteins containing TR (thyroid hormone receptor) or ER (estrogen receptor) ligand-binding domains (LBDs) and fragments of the coactivator protein, SRC-1. Specific, ligand-dependent interaction was demonstrated.

10 Mammalian cell lines containing a two-hybrid system comprising a reporter gene and two hybrid molecules: one containing a nuclear receptor LBD (TR or ER) fused to a VP16 acidic activation domain, and the second containing coactivator protein fragments having at least one leucine-charged domain (LCD) fused to a Gal4 DNA-binding domain, wherein the two hybrids can interact in a ligand-dependent manner leading to reconstitution of transcriptional activity with regard to 15 the reporter gene. The third LCD of SRC-1 was found to be dispensable for interaction with the TR and ER LBDs, and that the second LCD interacts preferentially with ER rather than TR. In addition, ligand-dependent dissociation of the Tr LBD from fragments of the corepressor proteins SMRT and NcoR was demonstrated in this format. No detectable interaction between these corepressor fragments and the ER LBD was observed in the absence of ligand. Novel peptide motifs which 20 interact with TR and/or ER activator functions in a receptor- and ligand-specific manner. Large random and focused (centered on the leucine charged motif, LXXLL) recombinant peptide diversity libraries were screened and novel sequences which interact specifically with ER were identified; estradiol increases the ability of these novel peptides to interact with the ER.

25 Example 1: Direct Interaction Assay

Fig. 1 is a schematic representation of an exemplary embodiment of a direct interaction assay format (ELISA) for measuring interaction of a nuclear receptor LBD with a binding fragment of steroid receptor coactivator-1 (SRC-1). The LBD of the nuclear receptor (ER = estrogen receptor, TR / = thyroid hormone receptor or form) fused in-frame to a glutathione S-transferase sequence (GST) to 30 form the binding member for the nuclear receptor LBD which is immobilized on a substrate indicated as a well surface, such as by electrostatic binding to a plastic 96-well plate. The coactivator member contains 3 leucine charged domains (LCDs) of SRC-1 fused in-frame to GST/MBP at the amino-terminus and fused in-frame to an antibody 179 epitope tag at the carboxy-terminus. The LCD sequences are shown. The SRC-1 fusion member that is bound to the immobilized LBD is detected 35 with a mouse antibody that specifically reacts with the 179 epitope and a second antibody (alkaline phosphatase conjugated antimouse Ab). Fig. 2 shows the results of the direct interaction assay using

ER LBD interacting with SRC-1. 0.5 µg of purified GST-ER was used with varying amounts of crude bacterial lysate containing GST-SRC-1. The interaction is specific (GST control) and enhanced by estradiol. Fig. 3 shows the results of the direct interaction assay using ER LBD interacting with SRC-1. 0.5 µg of purified GST-ER was used with varying amounts of crude bacterial lysate containing 5 GST-SRC-1. The interaction is specific (GST control) and enhanced by estradiol. Fig. 4 shows results of a direct interaction assay of the TR and TR LBDs interacting with SRC-1. The indicated amounts of GST fusion proteins were used. The interaction is specific and dependent on T3. Fig. 5 shows results of a direct interaction assay as a dose-response curve of T3 in promoting interaction between the TR and TR LBDs and SRC-1. T3 appears more potent on the receptor. Direct 10 protein-protein interactions can be detected in cell-free systems in a variety of formats, including phage-displayed proteins and purified proteins, among other formats evident to those skilled in the art.

Example 2: Positive Hybrid System:Coactivator

Fig. 6 shows a schematic portrayal of LRB-TRX, CA-TRX, and CR-TRX constructs used and the reporter polynucleotide of a two-hybrid system. "Receptor" indicates LBD-TRX, with the LBD exemplified by a generic nuclear receptor (NR) LBD with bound ligand (L), and the TRX domain represented by the VP16 acidic activation domain (VP16). "Coactivator" indicates a CA-TRX, with exemplary CA species being a portion of the SRC-1 protein, a portion of the CBP protein, or isolated LCD sequences from those proteins, the TRX domain is exemplified as the Gal4 DNA binding domain (DBD). "Corepressor" indicates a CR-TRX, with exemplary CR species being the interacting domains (ID1 or ID2) from SMRT or NcoR fused to the TRX domain as exemplified by Gal4 DNA binding domain (DBD). The reporter polynucleotide is exemplified as a UAS-TK-luciferase reporter containing binding sites for Gal4 DBD. CHO cells were triple transfected with these constructs and hormone added: Fig. 7 shows data from a positive two-hybrid system as a dose-response curve showing that 25 reporter (luciferase) is generated only when all three components (VP16ER, Gal4-SRC-1, and UAS-TK-luciferase) are transfected together, and that the response is dose-dependent with respect to estradiol concentration. Fig. 8 shows data from a positive two-hybrid system as a dose-response curve showing that reporter (luciferase) is generated only when all three components (VP16TR, Gal4-SRC-1, and UAS-TK-luciferase) are transfected together, and that the response is dose-dependent 30 with respect to T3 concentration.

Example 3: Positive Hybrid System:Corepressor

Fig. 9 shows coactivator/corepressor interactions with TR LBD in the positive two-hybrid system. NcoR ID1, and to a lesser extent SMRT ID1 interact with TR LBD, but neither ID2 35 interacts strongly with the LBD. T3 induced dissociation of the corepressor fragments at significantly lower concentrations than is required to recruit a coactivator. Fig. 10 shows interactions with ER LBD in the positive two-hybrid system. NcoR ID1, and to a lesser extent SMRT ID1 interact with ER LBD,

but neither ID2 interacts strongly with the LBD. None of the four IDs interact significantly with the ER LBD in the absence of ligand.

Example 4: Identification of Novel LCDs

5 Fig. 11 shows a schematic portrayal of a method for identifying novel LCD sequences from libraries of displayed peptides. Peptide libraries were constructed by fusing sequences to the Lac repressor (LacI). The encoding plasmid contains operator sites so that a bacterial lysate contains the displayed peptides bound to the encoding plasmid. The library was screened with immobilized GST-ER in the presence of estradiol in four rounds of enrichment.

10

Fig. 12 shows ELISA signals for LacI-fused peptides obtained from either a focused (-LXXLL-) or random (-XXXXX-) 15mer library in the presence of ER and estradiol.

15 Fig. 13 shows the sequences of LacI-fused peptides obtained by screening the library by ER panning. The top set of sequences was obtained from the focused (-LXXLL-) library and the bottom set was obtained from the random sequence (-XXXXX-) library. Notable amino acids are highlighted. Fig. 14 shows ELISA data from the fourth round selectants of the LacI-fusions (tetravalent reagent) which were subcloned as a population into an MBP vector (monovalent reagent) and random clones tested without estradiol. Control is SRC-1 fragment (597-781) containing the 3 LCDs. Fig. 15
20 shows ELISA data from the fourth round selectants of the LacI-fusions (tetravalent reagent) which were subcloned as a population into an MBP vector (monovalent reagent) and random clones tested with estradiol. Control is SRC-1 fragment (597-781) containing the 3 LCDs. Note the estradiol dependence of many of the clones for interaction with ER (compare data in Fig. 14 with Fig. 15). Fig. 16 shows the sequences of the selected clones. Notable amino acid residues are highlighted. Figure
25 17 shows a scheme for drug profiling as described further in the description of the drawings.

Example 5: Selection of Receptor-selective Peptides from "Headpiece-dimer" libraries

30 In order to more accurately characterize a subset of the peptides selected from libraries, we selected eight ER and TR selected peptide fusions for further analysis. In addition, MBP fusions to several of the SRC-1 fragments used in the initial M2H studies were constructed. Finally, for comparison to natural NR-boxes, we made MBP fusions to eleven 19mer peptides derived from the three SRC-1 family members, SRC-1, TIF-2, and RAC-3. These peptides were constructed to mimic the format of the focused X.LXXLLX "headpiece dimer"-derived peptides. We purified these proteins by affinity chromatography to ensure use of equal amounts in ELISA and competition binding assays (see below). Binding of purified SRC-1 NRID fragments to the immobilized receptors ER, ER, TR, and TR was determined. Through repeated experiments, we determined that with equal amounts of immobilized target receptor, the signal intensity with the SRC-1.NRID (SRC1+2+3) in the

ELISA varied little from receptor to receptor and that MBP alone gave consistently low signals. We therefore analyzed both natural and library-selected peptide fusions in the context of the specific signal obtained with SRC1+2+3. At the concentration of MBP fusions used, differences in the ability of relatively high affinity proteins (such as the NRID fragments) to interact with the immobilized receptors are not readily apparent. Therefore, for the NRID fragments the differences seen in the M2H assay are less apparent, however, lowest signal relative to SRC1+2+3 is with SRC2 and ER. This is consistent with the M2H assay where the difference in luciferase signal between SRC1+2+3 and SRC2 is greatest for ER. The actual differences in affinity between the NRID fragments is relatively small compared to differences seen in NR-box 19mer peptides. These results indicate that the interpretation of the minimum requirements for cofactor/NR interaction are likely highly assay type dependent.

Testing the MBP fusions containing natural coactivator-derived peptides by ELISA revealed striking differences in signal intensity between different peptides and between different receptors. As expected, SRC2 bound well to all four receptors while SRC1 bound less well to all four but especially poorly to the TRs. SRC3 also bound less well than SRC2 but preferred the TRs over the ERs as expected. Similar results were obtained with the other two SRC-1 family members, however, NR-box #3 of RAC-3 appears to bind to the ERs more strongly than to the TRs.

Analysis of purified MBP-peptides derived by selection from the peptide library indicated that there is general ER and TR selectivity of peptides selected on these two receptors respectively. The degree of selectivity predicted by this assay, however, is not as great as that predicted from the ELISA done with crude bacterial lysates. For instance, one ligand (M153) is quite ER selective in the assay using a crude lysate, while the purified MBP-peptide fusion appears equally effective at interaction with both ER and TR. This could be due to the nature of the assay as suggested above; in this case the absolute amount of the MBP fusion in the assay is likely far greater when using purified proteins, thus somewhat driving low affinity interactions. Although these peptides were selected with the α -forms of ER and TR, to a large extent the selectivities extend to the β -form of the respective receptor although some differences (for instance ligand M-693, TR vs. TR β) suggest that β selective peptides could be identified.

Example 6: Determination of receptor/coactivator-mimetic peptide interaction affinities by radio-competition assay

In order to assess the interactions of the natural and selected sequences by a more quantitative methodology, we set up a radio-competition assay using immobilized receptor LBDs and iodinated SRC-1-NRID (SRC1+2+3) as the tracer. We set up a homogeneous binding assay based

on scintillation proximity (SPA). Control experiments using unlabeled tracer as the competitor. Even in the absence of estradiol, ER interacts specifically and saturably with the NRID. The IC_{50} for SRC1+2+3 is 21nM without ligand but decreases ~5 fold to 4.3nM upon the addition of estradiol. In addition, as expected from the ELISA experiments, the amount of tracer bound to the immobilized receptor increases dramatically with ligand addition. TR does not interact measurably with the NRID in the absence of ligand, consistent with our observation of consistently much lower signals with TR in ELISAs as compared to ER in the absence of ligand. Addition of ligand to the TR SPA results in the expected association of the 125 I NRID and an IC_{50} of 5.1nM for unlabelled SRC1+2+3.

10 We next used the MBP fusions described in the previous section as competitors in both the ER -NRID and TR -NRID SPAs in the presence of estradiol and triiodothyronine respectively. To ensure that affinity and selectivity trends we observed were not artifacts of any one protein preparation, we re-isolated a second batch of several of the MBP fusions and repeated all measurements. Although there are some quantitative differences between the two protein
15 preparations, the results lead to the same conclusion in each case. As expected, the IC_{50} values for SRC1+2+3 and SRC2+3 are nearly identical (3-11nM) for the TR assay and these protein fragments are more potent than any natural or synthetic, single NRbox-containing peptide, assayed on this receptor. SRC1+2 and SRC2, either as a peptide (19mer) or fragment (~56mer), are less potent, consistent with the M2H assays above. Homologous peptides derived from the three SRC-1 family
20 members behave in a similar fashion with TR. The order of affinity of the three NR-boxes in each case is #2 > #3 > #1 suggesting, that at the level of NRID - AF2 interactions, TR displays no preference for any one of the three SRC-1 family members. Consistent with our M2H experiments, the amino-terminal NR-boxes of CBP and p300 have relatively poor affinity for the TR. While many of the TR -selected peptides have IC_{50} values similar to the best natural peptides, eg: SRC2, the ER -
25 selected peptides have low affinity for TR. The fold selectivity of the TR -selected peptides for the TR is always >2, except for ONE LIGAND (M-655), which we have shown by ELISA to bind to both TR and ER. In contrast, with few exceptions, most of the natural coactivator-derived peptides have receptor selectivities of only 1 - 2 fold. A greater fold selectivity of SRC3 for TR and TIF1 or RAC1 for ER is likely given the ELISA and M2H results.

30

The interactions of the natural coactivator-derived peptides or SRC-1 fragments with ER are slightly different than with TR, as expected. While SRC1+2+3 still has the lowest IC_{50} , there is little difference between the values obtained for SRC1+2 and SRC2+3 on ER, in contrast to those obtained for TR. SRC2, in fragment or peptide form, has lower affinity than the fusion proteins
35 containing more than one NR-box as predicted by M2H assay. In addition, the order of affinity of the three NR-boxes in each SRC-1 family member for ER is #2 > #3 = #1. From the data it appears that TIF-2 and RAC-3 were more effective coactivators of ER -dependent transcription than SRC-1, as the

affinities of the #1 and #3 NR-boxes of these proteins are significantly higher than those of the corresponding NR-boxes of SRC-1. While previous studies using yeast-two-hybrid systems have shown that the ER LBD is able to interact with the amino terminus of CBP (Kamei 1996) or with the amino terminal CBP NR-box (albeit poorly compared to the SRC NR-boxes, Heery 1997), our data suggest that these interactions are likely of quite low affinity. Peptides we selected using ER as the panning reagent show a relatively high degree of selectivity for ER over TR. As with the TR selected peptides and TR, the affinity of the ER -selected peptides for ER is similar if not slightly higher than the best natural NR-boxes. In addition, similar to the TR -selected peptides, these individual peptides do not have affinities for ER that are as high as any of the SRC-1 fragments containing more than one LXXLL motif. The experiments above demonstrate that screening peptide libraries with individual receptors is a successful method for obtaining receptor-selective peptides with affinities equal to or greater than the relatively non-selective natural NRbox-derived sequences.

The foregoing description of the preferred embodiments of the present invention has been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise form disclosed, and many modifications and variations are possible in light of the above teaching.

All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Such modifications and variations which may be apparent to a person skilled in the art are intended to be within the scope of this invention.

CLAIMS

1. A positive hybrid nuclear receptor signal transduction system, comprising an intact eukaryotic host cell, comprising: (1) a LBD-TRX polynucleotide sequence encoding and expressing a ligand-activatable fusion protein which comprises a ligand binding domain ("LBD") of a predetermined nuclear receptor covalently linked to a transcriptional activator domain ("AD") of a predetermined transcription factor, (2) a CA-TRX polynucleotide sequence encoding and expressing a coactivator fusion protein which comprises a domain of a nuclear receptor coactivator protein ("CA") capable of binding to said LBD of said predetermined nuclear receptor linked to a DNA-binding domain of a predetermined transcription factor, and (3) a reporter polynucleotide sequence comprising, in linear order, a transcriptional regulatory sequence which is responsive to said predetermined transcription factor and a reporter cassette encoding a sequence that confers a signal or detectable phenotype.
- 15 2. A positive hybrid nuclear receptor signal transduction system comprising an intact eukaryotic host cell, comprising: (1) a LBD-TRX polynucleotide sequence encoding and expressing a ligand-activatable fusion protein which comprises a ligand binding domain ("LBD") of a predetermined nuclear receptor covalently linked to a transcriptional activator domain ("AD") of a predetermined transcription factor, (2) a CR-TRX polynucleotide sequence encoding and expressing a corepressor fusion protein which comprises a domain of a nuclear receptor corepressor protein ("CR") capable of binding to said LBD of said predetermined nuclear receptor linked to a transcriptional activator domain of a predetermined transcription factor, and (3) a reporter polynucleotide sequence comprising, in linear order, a transcriptional regulatory sequence which is responsive to said predetermined transcription factor and a reporter cassette encoding a sequence that confers a signal or detectable phenotype.
- 25 3. A nuclear receptor signal transduction system, comprising a reverse hybrid reporter host cell containing: (1) an LBD-TRX polynucleotide sequence encoding a fusion protein comprising a ligand-binding domain of a nuclear receptor in polypeptide linkage a DBD or AD of a transcription factor; (2) a CR-TRX polynucleotide sequence encoding and expressing a corepressor fusion protein ("CR-TRX") which comprises a domain of a nuclear receptor corepressor protein ("CR") capable of binding to said LBD of said predetermined nuclear receptor linked to a transcriptional activator domain of a predetermined transcription factor (TRX), and (3) a relay (or signal inverter) gene encoding a protein which is efficiently expressed as a consequence of the LBD-TRX binding to the CR-TRX as a transcriptionally active complex, and (4) reporter gene comprising, in linear order, a transcriptional regulatory sequence responsive to said transcriptionally active complex, and a reporter cassette encoding a reporter, wherein the reporter gene is efficiently expressed then the product of

the relay (or signal inverter) gene is substantially absent and is either poorly expressed or not expressed when the relay (or signal inverter) gene is efficiently expressed.

4. A multiplexed format assay for identifying nuclear receptor ligands comprising
5 at least two of the following: (1) positive hybrid system:coactivator, (2) positive hybrid
system:corepressor, (3) reverse hybrid system:coactivator, (4) reverse hybrid system:corepressor, (5)
direct interaction assay, or (6) other art-know assay for identifying and/or quantifying ligand efficacy
and/or potency as an antagonist or agonist of nuclear receptors.

10 5. A method for identifying a candidate pharmaceutical agent from a library of
test agents, wherein the candidate pharmaceutical agent has a desired biological effect profile
comprising: (1) performing n (where n is a number greater than 2, preferably greater than 3, and less
than 10 billion) distinct assays of the invention individually using each discrete test agent (which may
be a mixture) of the library so as to obtain for each individual test agent measurements of at least n
15 biological effects as detected as a ligand-induced conformational change or a binding interaction
change in a discrete assay, (2) for each biological effect detected, assigning a score value (binary or
quantitative) based upon the detection (or lack thereof) of a ligand-induced conformational change or
binding interaction in each assay, separately, to generate a score matrix ("bioeffect fingerprint") for
each agent, and (3) comparing each agent's score matrix to an equivalent score matrix for one or
20 more predetermined agonist(s) and/or antagonist(s), and thereby identifying agents having score
matrices substantially similar to the score matrix of said predetermined agonist(s) or antagonist(s).

6. A polypeptide comprising a binding amino acid sequence that is: (1) non-
naturally occurring in a nuclear protein, and (2) predetermined to bind to a nuclear receptor, typically
25 by interaction with a binding interface of a nuclear receptor at which naturally-occurring coactivators
and/or corepressors bind.

7. A polypeptide of claim 6, wherein said polypeptide comprises a sequence
selected from the group of sequences shown in Fig. 16.

30

8. An agonist ligand of a nuclear receptor identified by the process of screening
a library of test agents with a positive hybrid nuclear receptor system, a reverse hybrid nuclear
receptor system, or a combination thereof, and selecting agonist ligands.

35

9. An agonist ligand of claim 8, wherein the process comprises the further step
of screening said library with a direct interaction assay, and selecting agonist ligands which are
detected as positives in each screening step.

*Nuclear Receptor - Cofactor
Interaction ELISA*

Receptors:

GST

ER/TR α/β

Coactivator:

GST/MBP

SRC-1
597-781

179

LCDs

632 KLVQLLTTT 640
689 ILHRLLQEG 697
748 LLRYLLDKD 756

Alk.phos.
anti-ms aby

anti-179 aby

GST-SRC-179

GST-LBD

well surface

+/- L

FIG. 1


GST ER α /GST SRC-1 ELISA

FIG. 2




FIG. 3

4/17



GST TR α / β - GST SRC-1 ELISA

FIG. 4


5/17

**FIG. 5**




6/17

Mammalian Two-hybrid Assay

Receptor



Coactivator



Corepressor



Reporter




FIG. 6

7/17

Mammalian 2-hybrid Coactivator Interaction Assay




FIG. 7

8/17

Mammalian 2-hybrid Coactivator Interaction Assay




FIG. 8

9/17




FIG. 9

10/17

Gal4-coactivator/corepressor
Interactions with VP16ER β LBD




FIG. 10

'Peptides-on-plasmids' libraries





FIG. 11

SUBSTITUTE SHEET (RULE 26)

12/17



13/17

ER_S lacI Sequences

<u>clone#</u>	<u>Sequence</u>	<u>ELISA Signal (+E2)</u>
Lib.	xxx x x x x x L x x L L x x x x x x x	
	-2 -1 +1 +2 +3 +4 +5	
16	V L E K R P I L R E L L R G P	
17	G R N G S V I L R R L L N S G G S Y S N	1.11
9	H S M N H S I L T R L L T S S V G M Q	0.95
21	C A R D M S K L Q R L L R G L P A	0.93
8	V G F S L R R L E T L L R E G R I N D	0.88
10	T R R E A S K L C S L L I G G	0.60
5	E T A K E S L L W R L L E R G S T E R	0.54
14	Q L A S S A K L V S L L Q S	0.52
13	R G N R L S R L S Q L L G N S E I G G	0.44
3	S S H K G S K L K S L L Q F G P	0.30
12	G G A R D T M L E A L L K C S G A G I N	0.29
Lib.	Random 15-mer	0.26
42	P I L R R L L T T R Q M R L I	0.40
31	G P Q T G S L L W K M L A E R	0.30
41	G S T M S I L L A E L L R R G	0.25
38	S V G I L R R E L E N K E E	0.22
44	R T Q S L L R T L L T A D L T	0.22

FIG. 13

14/17

MBP ELISA (-Estradiol)




FIG. 14

15/17

MBP-ELISA (+Estradiol)




FIG. 15

16/17

ER β MBP Sequences

(LXXLL) X X X X X X X L X X L L X X X X X X X X ELISA
SIGNAL
(+E2)

Random 15-MER

M-39	D T R M T I L L R L L T N Q S	0.81
M-27	G P Q T S L L W K M L A E R	0.64
M-45	E C S S W L L H Y L R S R D S	0.64
M-93	/ S I L L N L L T K D H Q W R N	0.64
M-97	L L L K L L Q R N P	0.61
M-37	N L L M R Y L M A K S D G V S	0.61
M-96	G R G L L E L L T R G D N A	0.44
M-38	G S L L E S L L R S R D G	0.43
M-29	E R L P G R L L W R M L M E R	0.42
M-25	E S V L L R L L R M D A T R V	0.38
M-31/M-35	W G S S L L V T Y L T Q R E M	0.35
M-28	Q M G G P L L W A Y L I G P L	0.33
M-91	G T G G S M L L W Y L S K D H	0.30

FIG. 16

17/17

Ligand

Direct
Interaction
Assay

Positive Hybrid Assays

Estradiol LigandX LigandY LigandZ Tamoxiphen

LBD-1 + CA-1	+	+	-	-	-
LBD-1 + CA-2	-	-	-	++	++
LBD-1 + CR-1	+	-	+	-	-
LBD-2 + CA-1	-	-	-	+/-	+
LBD-2 + CA-2	EC ₅₀ = 0.5nM	EC ₅₀ = 0.9nM	EC ₅₀ = 30nM	EC ₅₀ = 15nM	EC ₅₀ = 200nM
LBD-2 + CR-1	-	-	+	+	-
LBD-1 + CA-1	+++	++	+	+	+

←
estrogen-like

→
tamoxiphen-like

FIG. 17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/07168

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : G01N 33/53, 33/567, 33/542; C07K 2/00 4/00, 16/00

US CL : 435/7.2, 7.9; 530/300, 350 387.1, 388.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.2, 7.9; 530/300, 350 387.1, 388.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HEERY, et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 12 June 1997, Vol. 387, pages 733-736, see entire document, note the use of two hybrid assays and the LXXLL motifs.	1-9
X	TRAISH et al. Binding of site-directed monoclonal antibodies to an epitope located in the A/B region (amino acids 140-154) of human estrogen receptor-induced conformational changes in an epitope in the DNA-binding domain. Steroids. September 1996, Vol. 61, No. 9, pages 549-556, see entire document, note the a. antibodies to the estrogen receptor.	6

Further documents are listed in the continuation of Box C.



See patent family annex.

•	Special categories of cited documents:	• T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• A	document defining the general state of the art which is not considered to be of particular relevance	• X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• B	earlier document published on or after the international filing date	• Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step, when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	• &	document member of the same patent family
• O	document referring to an oral disclosure, use, exhibition or other means		
• P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

28 JUNE 1999

Date of mailing of the international search report

02 AUG 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. : (703) 305-3230

Authorized Officer

JOSEPH W. RICIGLIANO

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/07168

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LE DOUARIN, et al. A new version of the two-hybrid assay for detection of protein-protein interactions. Nucleic Acids Research. 11 March 1995, Vol. 23, No. 5, pages 876-878, see entire document.	1-5 and 8-9
Y	US 5,470,952 A (STAHL et al) 28 November 1995, see entire document, especially column 8 line 42 - column 9 line 23. Note that the references teaches the use of the two hybrid system to identify agonist or antagonist of hybrid complex formation.	5, 8, 9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/07168

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, Derwent, JPOABS, EPOABS

nuclear receptor, (steroid or thyroid or PPAR or TRX or retinoid) receptor, two-hybrid, three-hybrid, heterodimer, Fields, LXXLL, coactivator, corepressor.

THIS PAGE BLANK (USPTO)